ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Linda Harrison, Gustavo E Velásquez, Russell R Kempker, Marjorie Z Imperial, and 23 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5931694/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 6 You are reading this latest preprint version Abstract Background The standard of care (SOC) treatment for drug-susceptible pulmonary tuberculosis (DS-TB) consists of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). New treatment regimen options for DS-TB are needed as HRZE is long in duration (6 months), associated with frequent adverse events, unforgiving of adherence lapses, and complicated by rifamycin-based drug-drug interactions. The recent resurgence of TB drug development, particularly in the context of drug-resistant TB, offers promise for additional regimens for persons with DS-TB, provided they are sufficiently effective and well-tolerated. We spotlight wave 1 of the RAD-TB platform trial (ACTG A5409, NCT06192160) that will investigate new chemical entities for the treatment of DS-TB. Methods In wave 1 of the RAD-TB platform, adult participants initiating treatment for DS-TB will be randomized to SOC (HRZE, Arm 1) or one of five experimental arms for the 8-week intensive phase. The experimental treatment arms will consist of a bedaquiline and pretomanid backbone (BPa) in combination with one of three oxazolidinones. Arm 2 will study linezolid (BPaL) at a dose of 600 mg daily, Arms 3A and 3B will study TBI-223 at 1200 mg and 2400 mg daily, respectively, and Arms 4A and 4B will study sutezolid at 800 mg and 1600 mg daily, respectively. The primary efficacy objective is to compare sputum culture time to positivity (TTP) slope over the first 6 weeks of treatment for each experimental treatment arm to SOC. The primary safety objective is to compare new Grade 3 or higher adverse events over the first 8 weeks of treatment for each experimental treatment arm to SOC. After the intensive phase, all participants will receive the standard isoniazid and rifampicin (HR) continuation phase for 18 weeks and will be followed for 52 weeks after TB treatment initiation to assess long-term outcomes. Discussion Wave 1 of the RAD-TB platform aims to identify the optimal oxazolidinone(s), with regard to both efficacy and safety, to combine with the BPa backbone for the treatment of DS-TB. Subsequent waves of this platform trial may add a fourth drug to the regimen, study new diarylquinolines to substitute for bedaquiline, or study novel agents from other TB drug classes. Trials registration : ClinicalTrials.gov NCT06192160. Registered on January 5, 2024, https://clinicaltrials.gov/study/NCT06192160 tuberculosis drug-susceptible platform trial bedaquiline pretomanid linezolid TBI-223 sutezolid time to positivity early efficacy randomized controlled trial Figures Figure 1 Figure 2 Administrative information Note: The numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/). SPIRIT checklist items {26a}, {26b}, {11d}, {16b}, {16c}, {17a}, {17b}, {18a}, {18b}, {19}, {27}, {33}, {31c}, {5d}, {21a}, {23}, {25}, {31a}, {29}, {24}, {32} and {28} are solely covered in the Supplemental Appendix. Title {1} A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB) Trial registration {2a and 2b} ClinicalTrials.gov registration number NCT06192160 Protocol version {3} Version 2.0 as of March 21, 2024 Funding {4} The trial is funded by the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) under Award Numbers UM1 AI068634, UM1 AI068636, UM1 AI106701 and UM1 AI179699. Some RAD-TB wave 1 drugs will be donated or provided by the Global Alliance for Tuberculosis Drug Development (“TB Alliance”). Author Details {5a} See title page Name and contact information for the trial sponsor {5b} Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID) Melanie Goth, Medical Officer at DAIDS, [email protected] Role of sponsor {5c} DAIDS participated in the design of the RAD-TB trial and reviewed and approved the protocol prior to initiation. Additionally, TB Alliance reviewed the protocol prior to initiation. The content of publications of the RAD-TB trial are solely the responsibility of the authors and do not necessarily represent the official views of DAIDS, TB Alliance, or the institutions with which the authors are affiliated. Introduction Background and Rationale {6a} New innovations in the treatment of drug-susceptible pulmonary tuberculosis (DS-TB) are urgently needed to shorten treatment duration, enhance outcomes, and provide options for people who cannot tolerate standard therapy. The current standard of care (SOC) treatment for DS-TB was developed over 40 years ago ( 1 – 3 ). It is six-months in length consisting of a two-month intensive phase of isoniazid (INH, H), rifampicin (RIF, R), pyrazinamide (Z), and ethambutol (E), followed by a four-month continuation phase of INH and RIF [HRZE] ( 4 ). The HRZE regimen is generally effective but often needs to be prolonged beyond six months in persons with cavitary lung disease ( 5 ), is associated with low completion rates in some groups ( 6 ), is unforgiving of modest adherence lapses ( 7 ), can cause gastrointestinal, liver, eye, skin, and hypersensitivity adverse events ( 8 – 10 ), and is complicated by rifamycin-based drug-drug interactions ( 11 , 12 ). New drugs and regimens for DS-TB are needed to achieve a success rate of more than 90%, meet key priorities of the Global Plan to End TB ( 13 ), and provide better options for both TB providers and patients that more closely align with target regimen profiles set forth by the World Health Organization (WHO) ( 5 ). In the context of drug-resistant TB, there have been significant advances in regimen development resulting in the registration of bedaquiline (B) and pretomanid (Pa), which when given in combination with linezolid (LZD, L) [BPaL], achieved a 90% treatment success rate in the Nix-TB study (NCT02333799) in six months ( 14 , 15 ) but resulted in adverse events from LZD-related mitochondrial toxicity in a majority of participants, most commonly later in treatment (after the first eight weeks). A follow-on dose- and duration-ranging trial of the LZD component of BPaL, ZeNix (NCT03086486), showed that a lower starting dose of LZD at 600 mg daily resulted in a similar treatment success rate (91%), with fewer participants experiencing treatment-limiting anemia, thrombocytopenia, and neuropathy ( 16 ). Mouse models have shown that combinations like BPaL that include a diarylquinoline, nitroimidazole, and oxazolidinone, respectively, are highly efficacious with the oxazolidinone being a significant contributor to efficacy ( 17 – 20 ). BPaL has not been evaluated in clinical trials among persons with DS-TB, and descriptions of its use in persons with DS-TB are limited ( 21 , 22 ). Studying BPaL in DS-TB is important scientifically since, beyond providing a new treatment option for those with rifamycin-intolerant DS-TB, differences in populations who acquire DS-TB versus DR-TB and in the biology of rifamycin-susceptible versus rifamycin-resistant Mtb strains may lead to varying treatment responses ( 23 – 27 ). Knowledge of the efficacy of BPaL in DS-TB will additionally help to define a pan-TB regimen in the future. While microbiologic and clinical outcomes with BPaL are excellent, mitochondrial toxicities associated with LZD, such as optic and peripheral neuropathy and myelosuppression, are a concern. These toxicities are related to cumulative exposure to the drug and limit our ability to use LZD safely beyond the first 8 weeks of treatment. Other oxazolidinones are in development that are likely to have a lower risk of side effects, as some have inhibitory concentrations against mitochondrial protein synthesis that are significantly higher than LZD. One example, TBI-223, recently completed phase 1 testing ( 28 ), had a superior toxicity profile compared to LZD in toxicology studies, and had comparable efficacy when replacing LZD in combination with a diarylquinoline and Pa in mouse models ( 29 , 30 ). Secondly, sutezolid (SZD, S) has superior potency compared to LZD in vitro ( 31 ) and has demonstrated greater efficacy when administered alone and in combination with BPa in BALB/c mice ( 17 – 20 ). BALB/c mouse model data indicate that SZD together with BPa outperforms HRZE in bactericidal activity and probability of relapse at a dose of 50 mg/kg daily, which is equivalent to 600–800 mg daily in humans assuming comparable protein binding. SZD completed phase 2A early bactericidal activity (EBA) testing ( 32 , 33 ), and in the SUDOCU phase 2B trial SZD doses of 600 mg daily, 1200 mg daily, 600 mg twice daily and 800 mg twice daily in combination with bedaquiline, delamanid, and moxifloxacin were investigated. Preliminary safety data suggest there were no dose-limiting safety issues, and pharmacokinetic-pharmacodynamic (PK-PD) analyses suggested there was an exposure-response relationship ( 34 ). With multiple new chemical entities in the TB drug pipeline ( 35 , 36 ), several trials networks and consortia are planning studies of new multidrug regimens for participants with DS-TB [CRUSH-TB ( 37 ), PAN-TB ( 38 ), PanACEA ( 39 ), UNITE4TB ( 40 )], including our own network Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections [ACTG] ( 41 ). The ACTG will conduct the novel ‘ R andomized, A daptive, D ose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary TB’ (RAD-TB) (ACTG A5409, NCT06192160) platform trial ( 42 ). This paper spotlights wave 1 of the RAD-TB platform, where next-generation oxazolidinones in combination with BPa for the treatment of DS-TB are the primary focus. Trial Design {8} RAD-TB is a phase 2, open-label, randomized controlled trial with an adaptive design, evaluating new regimens for the treatment of DS-TB. The trial utilizes a platform protocol that allows for future concurrently randomized treatment regimens to be added in subsequent waves after participants have completed, and outcomes have been evaluated for, the current wave. Wave 1 In wave 1 of the RAD-TB platform trial, participants with DS-TB will be randomized to one of six arms (Fig. 1 ). The first two arms of wave 1 will consist of an 8-week SOC HRZE intensive phase (Arm 1) and an 8-week BPaL intensive phase (Arm 2). In Arms 3A and 3B, LZD will be replaced in the BPa combination with one of two different doses of TBI-223 (1200 mg and 2400 mg daily, respectively). Our current mechanistic PK-PD dose-response model suggests that a TBI-223 daily dose of 1200 mg or 2400 mg will provide responses in combination with BPa that are similar to LZD ( 29 ). In Arms 4A and 4B, LZD will be replaced in the BPa combination by one of two different doses of SZD (800 mg and 1600 mg daily, respectively). Our translational model indicates that human SZD doses of at least 800 mg daily will be similar to or better than LZD in combination with BPa. Wave 1 will enroll a planned 315 participants concurrently randomized to one of the six arms. Twice as many participants will be randomly allocated to the SOC HRZE arm (Arm 1, n = 90) compared to the five experimental treatment arms (Arms 2, 3A-B and 4A-B, n = 45 each, or 225 in total). This will ensure a stable within-trial SOC comparison arm. Participants will be treated for a total of 26 weeks; consisting of the 8-week intensive experimental phase followed by an 18-week SOC HR continuation phase. Primary efficacy and safety outcomes will be measured at 6 and 8 weeks after treatment initiation, respectively, and all participants will be followed for 52 weeks post-randomization to assess long-term outcomes. The first 20 participants randomized to each of the experimental treatment arms (Arms 2, 3A-B, 4A-B) who consent will undergo intensive sampling for PK analysis, and all experimental arm participants will undergo sparse PK sampling. Objectives {7} Co-Primary Objectives To compare mycobacteria growth indicator tube (MGIT) liquid culture time to positivity (TTP) slope over the first 6 weeks of treatment for each experimental treatment arm to the SOC arm. To compare new Grade 3 or higher adverse events (AEs) over the first 8 weeks of treatment for each experimental treatment arm to the SOC arm. Secondary Objectives To compare time to stable culture conversion by MGIT liquid culture by week 8 for each experimental treatment arm to the SOC arm. To compare MGIT liquid culture TTP slope over the first 8 weeks of treatment for each experimental treatment arm to the SOC arm. To compare new Grade 3 or higher AEs over 26 weeks of treatment for each experimental treatment arm to the SOC arm. To compare discontinuations of anti-TB drugs for any reason prior to 8 and 26 weeks of treatment for each experimental treatment arm to the SOC arm. To determine the dose- and exposure-response relationships between experimental drug estimated PK parameters with safety and efficacy. To compare a composite of efficacy and safety outcomes using a risk-benefit approach for each experimental treatment arm to the SOC arm. To compare MGIT liquid culture TTP slope over the first 6 weeks of treatment for Arms 3A-3B and Arms 4A-4B compared to Arm 2 (BPaL). To compare durable cure defined by 52 weeks after treatment initiation in each experimental treatment arm to the SOC arm. Methods: Participants, interventions, and outcomes Study Setting {9} The RAD-TB platform trial will be conducted at international sites of the ACTG trials network located in 13 countries in Africa, Asia, and South America. Eligibility Criteria {10} Inclusion Criteria Overall, the RAD-TB platform trial will recruit adult participants (≥ 18 years) who have active pulmonary DS-TB and are initiating a course of therapy. Key inclusion criteria are Pulmonary TB identified by a sputum specimen within 7 days of entry that is positive for Mycobacterium tuberculosis ( Mtb ) and has a semiquantitative result of medium or high by Xpert No prior history of TB treatment within the last five years Documentation of susceptibility to INH and RIF For individuals with HIV, a CD4 count ≥ 100cells/mm 3 and currently or planned to be treated with dolutegravir-based antiretroviral therapy Normal laboratory values, a Karnofsky score ≥ 60, intention to follow contraception requirements, and ability and willingness to provide informed consent Exclusion Criteria Participants with more than 7 days of treatment for the current episode of active TB, extrapulmonary TB, Grade 2 or higher peripheral neuropathy, a QTcF interval > 450 ms, a weight < 35 kg, or a history of congenital QT prolongation, heart failure, hypothyroidism, bradyarrhythmia, or torsades de pointes will be excluded. Because the safety and efficacy of experimental compounds in this early phase trial have not yet been sufficiently established, individuals who are currently pregnant or breastfeeding will be excluded. See the Supplemental Appendix for a full list of the inclusion and exclusion criteria. Interventions Explanation for choice of comparator {6b} The study interventions are given during the first 8 weeks of TB treatment and the primary comparator regimen is HRZE SOC (Arm 1). HRZE was chosen as the primary comparator since it is the WHO-recommended regimen for pulmonary DS-TB, thus allowing for a direct comparison of the experimental treatment regimens with the current SOC. This trial also utilizes a second comparator regimen in BPaL (Arm 2). While the primary analysis will compare experimental treatment regimens to HRZE, BPaL will secondarily be compared to the other experimental treatment arms and was chosen since it is a WHO-recommended regimen for DR-TB and its use as an additional internal comparator will enable more informative ranking and prioritization of regimens (See the section on ‘Methods for additional analyses’ {20b} below for more details). Specifically, comparison of the novel BPa-containing regimens with BPaL will allow for direct comparison of the safety and microbiologic activity of different oxazolidinones. Intervention description {11a} Control and experimental treatment regimens (weeks 1–8) in wave 1 of the RAD-TB platform are displayed in Fig. 1 and outlined below: Arm 1: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol [HRZE] Arm 2: Bedaquiline, Pretomanid, Linezolid [BPaL] Arm 3A: Bedaquiline, Pretomanid, TBI-223 (1200mg) Arm 3B: Bedaquiline, Pretomanid, TBI-223 (2400mg) Arm 4A: Bedaquiline, Pretomanid, Sutezolid (800mg) Arm 4B: Bedaquiline, Pretomanid, Sutezolid (1600mg) All drugs will be given once daily with the doses specified in Fig. 1 and will be provided by the study through week 8. Bedaquiline will be given with a loading dose of 400 mg daily for the first two weeks followed by 200 mg daily for six weeks. After week 8, through week 26, all participants will receive the HR continuation phase through their in-country national TB program (NTP) at doses shown in Fig. 1. Pyridoxine (vitamin B6) will be given with INH based on current local dosing guidelines. Criteria for discontinuing or modifying allocated interventions {11b} Treatment Interruptions Study participants will have up to 70 days (10 weeks) from entry to complete 56 doses (8 weeks) of experimental treatment. Any missed doses should be made up with the same combination of drugs that were missed. For all arms during the first 8 weeks, a partial missed dose, where some but not all study drugs in the assigned regimen were taken, will be considered a full missed dose and will need to be made up at the end of the 8-week experimental treatment period. Treatment Discontinuation Participants who develop a Grade ≥ 3 AE or toxicity thought to be secondary to study drugs or of unknown etiology must be discussed by the site investigator with the trial clinical management committee (CMC), will have all study-provided drugs permanently discontinued, and will be referred to the NTP for completion of their TB treatment according to local SOC. If study-provided drug is permanently discontinued, participants will still be followed through the 52-week visit. If a participant develops visual changes which are considered likely due to the oxazolidinone, then the oxazolidinone (and other study-provided drugs) will be permanently discontinued at any grade of presumed optic neuritis. Participants who become pregnant or begin breastfeeding during the study will be discontinued from study-provided drugs and referred to the NTP for the treatment of their TB according to local SOC, and to a prenatal or postnatal care program for management of their pregnancy or breastfeeding, respectively, according to local SOC. Full criteria for permanent and premature study treatment discontinuation are provided in the Supplemental Appendix. Strategies to improve adherence to interventions {11c} Directly observed therapy (DOT) will be performed throughout TB treatment. Each site must follow local TB guidelines about DOT. All drugs must be taken orally, 7 days per week. At least five doses per week must be administered as DOT. Video DOT, use of community health workers, or other strategies used locally for delivering observed therapy are acceptable. Doses taken on weekends and on holidays may be under DOT or self-administered, as permitted by local TB guidelines. Data on adherence including pill intake will be recorded on standardized electronic case report forms (eCRFs). Participants with lower adherence (< 95%) will be provided counseling by the site. Additionally, all study participants will have adverse event counseling performed by study staff at entry, and at study weeks 1, 2, 3, 4, 6 and 8. Provisions for post-trial care {30} Participants who prematurely discontinue study treatment will be referred to their NTP or local clinic for treatment of their TB according to local SOC, but will be encouraged to continue on study, off study treatment, and receive all evaluations per the schedule of evaluations (SOE) through week 52 (Table 1). The composition of the treatment regimen once a participant is discontinued from the study will be at the discretion of the local clinician, with the trial CMC available as needed to advise. Outcomes {12} Primary Efficacy Outcome Measure and Estimand The primary efficacy outcome is measured by TTP from longitudinal MGIT liquid culture measurements at weeks 0, 1, 2, 3, 4 and 6 of treatment. The primary efficacy estimand is the difference in mean (experimental arm versus SOC) log 10 TTP slope from longitudinal MGIT liquid culture measurements over the first 6 weeks of treatment. Primary Safety Outcome Measure and Estimand The primary safety outcome measure is a new Grade 3 or higher AE through week 8 of treatment. The primary safety estimand is the difference in cumulative proportion (experimental arm versus SOC) of individuals having at least one new Grade 3 or higher AE by week 8 of treatment. Secondary Outcome Measures The secondary outcome measures are, as follows: Stable sputum culture conversion by week 8 as measured by culture negative status via MGIT liquid culture at two consecutive measurements. TTP slope from longitudinal MGIT liquid culture measurements over the first 8 weeks of treatment. New Grade 3 or higher AE through week 26 of treatment. Permanent discontinuation of study-provided anti-TB drugs due to any reason prior to week 8 of treatment. Permanent discontinuation or temporary discontinuation for ≥ 3 days of at least one anti-TB drug due to any reason prior to week 8 of treatment. Permanent discontinuation of at least one anti-TB drug due to any reason prior to week 26 of treatment. A composite of stable culture conversion at week 6 of treatment and no new Grade 3 or higher AE through week 8. Durable cure by 52 weeks after treatment initiation. Other Outcome Measures Other outcome measures are, as follows: Projected hazard ratio comparing time to stable culture conversion for each experimental treatment arm to SOC. Sputum ribosomal RNA synthesis (RS) ratio over the first 8 weeks of treatment and at 26 weeks of treatment (43). MGIT liquid culture results at weeks 1, 2, 3, 4, 6, and 8 of treatment. Participant timeline {13} Following informed consent, individuals will be screened for the trial to determine if inclusion and exclusion criteria are met. Eligible participants will be randomized to a treatment assignment at entry. Post-entry, scheduled evaluations will take place weekly until week 4, every two weeks until week 12, then at weeks 16, 20, 26 and 52. Additionally, unscheduled visits will occur at premature treatment or study discontinuation, or when a possible poor treatment response is suspected at or after week 16. Table 1 displays the planned evaluations at each visit [See Supplemental Fig. 1 for the SPIRIT figure]. Sputum for mycobacterial culture in liquid media will be collected at each visit with two sputum samples collected at entry and weeks 4, 6 and 8. At participating sites, open-ended qualitative interviews will be conducted in consenting participants to explore patient preferences for treatment regimens using systematic qualitative methods (44). Sample Size {14} The sample size in wave 1 will be 45 participants in each experimental treatment arm and 90 participants in the SOC arm (Arm 1). Assuming that 10–12% of participants will undergo late exclusion, withdraw from the study, or have several missing TTP measurements, we based the power simulation on 80 evaluable participants in the efficacy set in the SOC arm, and 40 in each experimental treatment arm. Using longitudinal liquid culture data from the HRZE arm of a recent large, international Phase 3 trial (TBTC Study 31/ACTG A5349, NCT02410772) (45), we estimated a baseline (intercept) TTP of 0.91 log 10 days and a TTP slope of 0.13 log 10 days per week via a linear mixed-effects model with an additive random intercept (SD = 0.101) and slope (SD = 0.353) plus a multiplicative random error (SD = 0.161). Using these estimates, TTP outcomes over 6 weeks were simulated (1,000 replicates) for a SOC and experimental treatment arm with right-censoring of TTP greater than 42 days. For each simulated dataset, a linear mixed-effects model on the log 10 TTP scale accounting for TTP censoring was fit. Based on this simulation, the trial will provide over 90% power to detect a difference in log 10 TTP slopes of at least 35% with a two-sided 5% significance level for each experimental treatment arm compared to SOC (Fig. 2A). As an example, if the average baseline TTP is 0.91 log 10 days = 8.1 days and the TTP increase is 0.13 log 10 days per week in the SOC arm, then by week 4 the TTP will be an average of 27 days for the SOC arm. The trial will have over 90% power to detect a 35% increase in slope on the log 10 TTP scale (Fig. 2B). This translates to being powered to detect an average TTP of 41 days by week 4 for an experimental arm. No adjustment for multiple testing is planned. Recruitment {15} Persons presenting to an international ACTG study site with at least one sputum specimen positive for Mtb by Xpert MTB/RIF Ultra at a medium or high semiquantitative level will be invited to screen for the study. The details of the study will be carefully discussed, and the candidate will be asked to read and sign the informed consent form (ICF). Those who agree will enter screening and will be assessed for eligibility by a local study investigator. If they meet all inclusion and none of the exclusion criteria they will be enrolled. Recruitment to wave 1 is anticipated to take approximately 12 months. Assignment of interventions: allocation Sequence generation {16a} In wave 1, participants will be randomly assigned to Arm 1 (SOC) or to one of the five concurrently enrolling experimental treatment arms (Arms 2, 3A-B or 4A-B) in a 2:1:1:1:1:1 ratio. Randomization will be conducted using permuted blocks within each of two strata defined by a medium versus high semiquantitative Mtb result by Xpert MTB/RIF Ultra. Additionally, randomization will be dynamically balanced by site. Statistical Methods Statistical methods for primary and secondary outcomes {20a} In wave 1, all comparisons will primarily be made between concurrently randomized experimental treatment and the SOC arm. Using TTP measurement from longitudinal MGIT liquid culture measurements at weeks 0, 1, 2, 3, 4 and 6 of treatment, we will estimate the difference in the mean (experimental arm versus SOC) log 10 TTP slope over the first 6 weeks of treatment. This primary efficacy outcome will be analyzed in the efficacy set of all randomized participants who take at least one dose of study treatment who do not undergo late exclusion due to either a negative baseline culture or drug resistance by baseline phenotypic testing. Table 2 provides the full estimand and analysis details [per the ICH addendum (46, 47)]. For the primary safety outcome measure, the difference in the cumulative proportion (experimental arm versus SOC) of an individual having at least one new grade 3 or higher AE by week 8 of treatment will be estimated. This outcome will be analyzed in the safety set of all randomized participants who take at least one dose of study treatment (See Table 2 for a full specification of the planned analysis). Details of the planned analysis for the secondary outcome measures are in the Supplemental Appendix. Interim Analyses {21b} We devised an interim safety stopping guideline to allow early discontinuation of experimental treatment arms if they are unlikely to meet a safety guideline at the end of wave 1 (specified in the next section). The interim safety stopping guideline will be assessed when approximately half the participants in the wave have been randomized and reached 8 weeks of follow-up. At this time the observed difference in the cumulative proportion of new Grade 3 or higher AEs by week 8 for each experimental treatment arm compared to the SOC arm will be estimated. If there is a > 30% higher observed probability of a new Grade 3 or higher AE through week 8 compared to SOC, the independent interim review committee will consider stopping that experimental treatment arm. For example, if 9 participants out of 22 (41%) experience a new grade 3 or higher AE on an experimental treatment arm compared to 4 out of a 45 (9%) on the SOC arm, the interim safety stopping guideline will be met. This safety stopping guideline is informed by assuming that approximately 10% of participants in the SOC arm will experience a new Grade 3 or higher AE by week 8 (based on data from S31/A5349 (45)). Given this, when the true difference between an experimental treatment arm and the SOC arm is 40%, there is a high chance (~ 81%) of meeting the stopping guideline. Whereas, when there is truly no difference between an experimental treatment arm and the SOC arm there is a very low chance (< 1%) of meeting the stopping guideline (See Table 3). Additionally, if the interim safety stopping guideline is met there is a high chance the regimen will be unlikely to be considered at the end of wave 1 for further development based on the safety guideline for ranking regimens provided in the next section. Wave 1 will also undergo additional regular safety reviews (see details in the Supplemental Appendix). Methods for additional analyses {20b} When ranking the TB regimens in wave 1 and deciding which regimens to move forward into subsequent waves of the RAD-TB platform (with four-drug regimens, for example), the totality of internal trial evidence, as well as evidence external to the trial, will be considered. A regimen that has a > 15% higher observed probability of a new grade 3 or higher AE through week 8 compared to SOC will be unlikely to be considered. Once a regimen passes this safety guideline, the primary efficacy analysis (TTP slope over the first 6 weeks of TB treatment) will be considered to rank regimens, along with the regimen’s risk-benefit profile, the regimen’s overall safety and tolerability profile, and PK parameters. Additionally, the mean difference in TTP slopes and associated 95% CIs over the first 6 weeks of treatment for Arms 3A-3B and Arms 4A-4B will be compared to Arm 2. Methods in analysis to handle protocol nonadherence and any statistical methods to handle missing data {20c} The analysis for the primary efficacy and safety outcomes will primarily use a treatment policy approach (46) for intercurrent events via an intention-to-treat analysis strategy (See Table 2). Supplemental analyses will consider a while-on-treatment approach for non-minor treatment changes. Participants with a missing TTP will be considered missing at random given observed TTP measurements and the randomized arm. Participants with an inability to produce sputum with or without induction will be assumed to have a TTP > 42 days and to be culture negative. Oversight and Monitoring Adverse event reporting and harms {22} Severity of AEs will be graded according to the DAIDS Table (48), except for creatinine, peripheral neuropathy, QT, visual acuity, and color vision, which will use trial-specific severity grading scales. Throughout trial follow-up, all Grade ≥ 1 non-laboratory AEs, Grade ≥ 2 laboratory AEs, all AEs of special interest, all AEs that lead to a change in study treatment, and any AEs meeting the serious AE (SAE) definition or expedited AE (EAE) reporting requirement (49) will be recorded on the eCRFs within 3 days. AEs of special interest include those related to oxazolidinone use including peripheral neuropathy, optic neuritis, and cytopenias as well as QT prolongation and increased transaminases. Discussion The ultimate aim of the RAD-TB platform trial is to build an optimized four-drug regimen for the treatment of DS-TB that will have superior efficacy compared to HRZE, the potential to shorten treatment duration, and safety and tolerability that is at least as good as HRZE. Currently, clinicians caring for patients with DS-TB do not have many trial-proven alternatives. Here, we have described the study protocol for wave 1 of the RAD-TB platform trial. Wave 1 will consist of six randomized treatment arms to identify the best oxazolidinone(s) to combine with the BPa backbone. Subsequent waves of the RAD-TB platform trial may include further refinement of successful regimen(s) identified in wave 1 to construct a four-drug regimen for DS-TB; this may include addition of a fourth drug or dose-ranging evaluations of novel agents from different drug classes. The study design of the RAD-TB platform trial is innovative in at least four ways. First, RAD-TB includes a strategy to rank the regimens within a wave before advancing regimens to the next wave of the platform. At the end of a wave, a safety guideline will be applied before assessment of efficacy, followed by consideration of other factors such as the regimen’s risk-benefit profile and PK parameters. The wave has been designed to include an interim safety review at 50% information so that regimens that are unlikely to meet the end-of-wave safety guideline are stopped early. Second, RAD-TB includes an SOC comparator arm composed of the WHO-recommended treatment for DS-TB, HRZE (Arm 1) ( 4 ), as well as a second comparator of BPaL (Arm 2); a current WHO-recommended treatment for DR-TB ( 50 ). This allows for a within-trial comparison to a second comparator where only one component of the regimen will be modified relative to the experimental arms. For example, a within-trial comparison of TTP slope will be made between BPaL (Arm 2) and BPa with TBI-223 at 1200 mg daily (Arm 3A). The inclusion of BPaL will also provide a first-ever benchmark of BPaL head-to-head against HRZE in DS-TB. Third, the primary efficacy readout will use longitudinal liquid culture TTP measurements over the first 6 weeks of treatment. The TTP slope will be modeled using analysis techniques appropriate for right-censoring as well as for repeated measures within participants. This allows for an efficient assessment of efficacy in an early phase trial of new TB treatment combinations ( 51 ). Fourth, RAD-TB will conduct dose-finding within the same trial infrastructure with two arms for both TBI-223 (Arms 3A and 3B) and SZD (Arms 4A and 4B). This enables efficient determination of the optimal dose of these two oxazolidinones and assessment of dose-response. RAD-TB puts forward a paradigm-changing advancement in TB drug development. Internally, we refer to RAD-TB as a ‘Phase 2A+’ design. Having completed Phase 1 testing, TBI-223 will bypass dedicated EBA monotherapy trials (‘Phase 2A’) in its FDA registration pathway. This has opened a new accelerated drug development pathway, which TBAJ-876 ( 52 ) has also followed. The RAD-TB design permits this through its rich sputum sampling in the intensive phase which, coupled with translational modeling predictions ( 53 ), will provide efficacy and safety data for TBI-223 that will stand in for the data generated in Phase 2A. And, as a dose-ranging study of combination therapy with follow-up through 52 weeks post-randomization, RAD-TB will serve the role of what is traditionally considered a Phase 2B trial for both TBI-223 and SZD. This is a welcome advance for TB drug development, where Phase 2A studies have been instrumental to the evaluation of the efficacy of single drugs — but are susceptible to false negatives where lack of robust EBA may be misconstrued as lack of contribution to multidrug therapy. A salient example is pyrazinamide, which has modest EBA but high sterilizing activity ( 54 ). Pyrazinamide was critical in shortening standard therapy for DS-TB from 9 to 6 months ( 1 ). Wave 1 of the RAD-TB trial will generate critical performance and safety data on two novel, promising oxazolidinones, SZD and TBI-223, among persons with DS-TB. While LZD has become a cornerstone drug for the treatment of multidrug- and extensively drug-resistant TB ( 50 ) based on efficacy demonstrated in the Nix-TB, ZeNix, and TB-PRACTECAL trials ( 15 , 16 , 55 ), concerns remain regarding its high rate of AEs, especially when given for more than two months. LZD is associated with myelosuppression and peripheral neuropathy resulting in dose reduction or treatment interruption in many patients. AEs are related to the off-target binding of LZD to mammalian mitochondrial ribosome leading to the inhibition of mitochondrial protein synthesis. The narrow therapeutic window of LZD along with a scarcity of data among persons with DS-TB necessitates further study into alternative oxazolidinones. SZD is a thiomorpholine structural analogue of LZD that was developed alongside LZD but has taken a protracted path to being rigorously tested for TB treatment ( 56 ). A promising characteristic of SZD is its enhanced potency against Mtb including being more active in caseum ( 57 ). The minimum inhibitory concentrations of SZD against Mtb clinical isolates have been found to be three times lower than LZD and murine studies have found greater efficacy of BPa and SZD regimens ( 58 ) versus first-line drug-susceptible therapy and also versus BPa and LZD regimens ( 17 ). Additionally, the main metabolite of SZD, U-101603, which is more abundant than the parent compound, has activity against Mtb and appears more active against non-replicating bacteria. Early clinical studies have found SZD to be safe and have bactericidal activity when given for 14 days ( 31 ). TBI-223 is a newly developed oral oxazolidinone with high bioavailability and substantially reduced inhibition of mammalian mitochondrial protein synthesis. It was developed to optimize the efficacy and safety of oxazolidinone therapy. TBI-223 has activity against drug-susceptible and resistant Mtb isolates from all global lineages and against replicating and non-replicating Mtb . In a murine model, TBI-223 has demonstrated similar bactericidal and sterilizing ability to LZD ( 30 ). The main advantage of TBI-223 over LZD is its reduced potential for AEs given its low rate of mitochondrial protein synthesis inhibition. Utilizing available pre-clinical and clinical data for SZD as well as unpublished data for TBI-223, our translational pharmacology and modeling tools indicate that BPa with either SZD or TBI-223 will perform as well or better than LZD ( 29 ). Findings from RAD-TB will thus provide a critical direct comparison of the safety and efficacy of these two promising oxazolidinones, helping to define their role in treating TB. In summary, RAD-TB is a platform trial studying early efficacy and safety of TB combination regimens within the ACTG trials network. Wave 1 of the RAD-TB platform will efficiently assess the best oxazolidinone(s) to use in combination with bedaquiline and pretomanid. Subsequent waves will build a safe and well-tolerated regimen that has the potential to be highly efficacious and reduce treatment length. The regimens efficiently identified by the RAD-TB platform will enable future studies of promising combinations that assess long-term outcomes in a large number of participants. Trial Status At present, the trial is pending its first enrollment at Protocol version 2.0 dated March 21, 2024. The study opened to screening on February 3, 2025. Accrual in Wave 1 is anticipated to take approximately 12 months after enrollment of the first participant, so Wave 1 recruitment is expected to be completed around March 1, 2026. Abbreviations DS-TB, drug-susceptible tuberculosis; BPaL, bedaquiline, pretomanid, linezolid; HRZE, isoniazid, rifampicin, pyrazinamide, ethambutol; RAD-TB, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel regimens for the Treatment of Pulmonary Tuberculosis Declarations Acknowledgements Authors contributions {31b} LJH, GEV and RK wrote the first draft of the manuscript. All authors reviewed and approved the final manuscript. Funding {4} The ACTG A5409 (RAD-TB) platform trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH) under award numbers UM1 AI068634, UM1 AI068636, UM1 AI106701, and UM1 AI179699. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. References Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231–79. Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J. 2002;20(Supplement 36):S87–94. Murray JF, Schraufnagel DE, Hopewell PC. Treatment of Tuberculosis. A Historical Perspective. Ann Am Thorac Soc. 2015;12(12):1749–59. WHO. WHO consolidated guidelines on tuberculosis. Module 4: Treatment - Drug-susceptible tuberculosis treatment. [Internet]. 2022 [cited 2024 Apr 16]. Available from: https://www.who.int/publications/i/item/9789240048126 World Health Organization. Target regimen profiles for tuberculosis treatment, 2023 update. World Health Organization; 2023. CDC. 2021 State and City TB Report [Internet]. [cited 2024 Apr 16]. Available from: https://www.cdc.gov/tb/statistics/indicators/2021/completionTherapy.htm Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708–15. Tweed C, Wills G, Crook A, Meredith S, Nunn A, Mendel C et al. P119 Using adverse events in a tuberculosis trial to describe the tolerability of standard therapy. 2016. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–95. CDC. Core Curriculum on Tuberculosis. What the Clinician Should Know [Internet]. [cited 2024 Jul 17]. Available from: https://www.cdc.gov/tb/media/Core_Curriculum_TB_eBook.pdf Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug–drug interactions with rifamycins. Clin Pharmacokinet. 2014;53:489–507. Semvua HH, Kibiki GS, Kisanga ER, Boeree MJ, Burger DM, Aarnoutse R. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. Ther Drug Monit. 2015;37(1):22–32. Stop TB, Partnership. Global Plan to End TB: A blueprint of priority actions and estimate of financial resources needed to end TB [Internet]. [cited 2024 May 28]. Available from: https://www.stoptb.org/global-plan-to-end-tb/global-plan-to-end-tb-2023-2030 US Food and Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs [Internet]. [cited 2024 Jul 22]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893–902. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):810–23. Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, et al. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother. 2016;60(1):270–7. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, et al. Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 2012;56(6):3114–20. Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, et al. Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis. Am J Respir Crit Care Med. 2009;180(4):371–6. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, et al. Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model. Antimicrob Agents Chemother. 2009;53(4):1314–9. Goswami ND, Ashkin D, Haley CA. Pretomanid in the treatment of patients with tuberculosis in the United States. N Engl J Med. 2022;387(9):850–2. Haley CA, Schechter MC, Ashkin D, Peloquin CA, Peter Cegielski J, Andrino BB, et al. Implementation of bedaquiline, pretomanid, and linezolid in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant tuberculosis disease. Clin Infect Dis. 2023;77(7):1053–62. Cheng N, Wu S, Luo X, Xu C, Lou Q, Zhu J et al. A comparative study of chest computed tomography findings: 1030 cases of drug-sensitive tuberculosis versus 516 cases of drug-resistant tuberculosis. Infect Drug Resist. 2021;1115–28. Li D, He W, Chen B, Lv P. Primary multidrug-resistant tuberculosis versus drug-sensitive tuberculosis in non-HIV-infected patients: Comparisons of CT findings. PLoS ONE. 2017;12(6):e0176354. Allué-Guardia A, García JI, Torrelles JB. Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front Microbiol. 2021;12:612675. Dawson R, Narunsky K, Carman D, Gupte N, Whitelaw A, Efron A, et al. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2015;19(7):780–6. Tweed C, Wills G, Crook A, Amukoye E, Balanag V, Ban A, et al. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. Int J Tuberc Lung Dis. 2021;25(4):305–14. ClinicalTrials.gov. A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults [Internet]. [cited 2024 Jul 17]. Available from: https://clinicaltrials.gov/study/NCT03758612 Strydom N, Ernest JP, Imperial M, Solans BP, Wang Q, Tasneen R, et al. Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen. Nat Commun. 2024;15(1):7311. Li SY, Converse PJ, Betoudji F, Lee J, Mdluli K, Upton A, et al. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model. Antimicrob Agents Chemother. 2023;67(4):e0003523. Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T et al. Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis. Pett SL, editor. PLoS ONE. 2014;9(4):e94462. Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, et al. Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis. Antimicrob Agents Chemother. 2011;55(2):567–74. Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, et al. Pharmacokinetics and Whole-Blood Bactericidal Activity against Mycobacterium tuberculosis of Single Doses of PNU‐100480 in Healthy Volunteers. J Infect Dis. 2010;202(5):745–51. Heinrich N, Opportunistic Infections (CROI). PanACEA SUDOCU Combination Dose-finding Trial Shows Sutezolid is a Safe Oxazolidinone [Internet]. Conference on Retroviruses and ; 2023 [cited 2024 Apr 16]; Seattle, USA. Available from: https://www.croiconference.org/abstract/panacea-sudocu-combination-dose-finding-trial-shows-sutezolid-is-a-safe-oxazolidinone/ Ignatius EH, Dooley KE. New Drugs for the Treatment of Tuberculosis. Clin Chest Med. 2019;40(4):811–27. Working Group on New TB Drugs. 2024 Global New TB Drug Pipeline [Internet]. [cited 2024 Apr 16]. Available from: https://www.newtbdrugs.org/pipeline/clinical ClinicalTrials.gov. Short-course Regimens for the Treatment of Pulmonary Tuberculosis (CRUSH-TB) [Internet]. [cited 2024 Apr 16]. Available from: https://clinicaltrials.gov/study/NCT05766267 ClinicalTrials.gov. Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis [Internet]. [cited 2024 Apr 16]. Available from: https://clinicaltrials.gov/study/NCT05971602 ClinicalTrials.gov. PanACEA - STEP2C -01 [Internet]. [cited 2024 Apr 16]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05807399 Boeree MJ, Lange C, Thwaites G, Paton N, De Vrueh R, Barros D, et al. UNITE4TB: A new consortium for clinical drug and regimen development for TB. Int J Tuberc Lung Dis. 2021;25(11):886–9. ACTG. Advancing Clinical Therapeutics Globally (ACTG) for HIV/AIDS and Other Infections [Internet]. [cited 2024 Apr 16]. Available from: https://actgnetwork.org/ ClinicalTrials.gov. Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB) [Internet]. [cited 2024 Apr 16]. Available from: https://clinicaltrials.gov/study/NCT06192160 Walter ND, Born SE, Robertson GT, Reichlen M, Dide-Agossou C, Ektnitphong VA, et al. Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. Nat Commun. 2021;12(1):2899. Corbin J, Strauss A. Basics of qualitative research: Techniques and procedures for developing grounded theory. Sage; 2014. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021;384(18):1705–18. International Conference on Harmonisation (ICH). Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Statistical Principles for Clinical Trials E9 (R1) [Internet]. 2019 [cited 2024 Apr 16]. Available from: https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf Kang M, Kendall MA, Ribaudo H, Tierney C, Zheng L, Smeaton L, et al. Incorporating estimands into clinical trial statistical analysis plans. Clin Trials. 2022;19(3):285–91. Division of AIDS (DAIDS). Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events [Internet]. 2017 [cited 2024 Apr 16]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf Manual for Expedited Reporting. of Adverse Events to DAIDS [Internet]. [cited 2024 Jul 9]. Available from: https://rsc.niaid.nih.gov/clinical-research-sites/manual-expedited-reporting-adverse-events-daids WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment - Drug-resistant tuberculosis treatment [Internet]. 2022 [cited 2024 Jul 23]. Available from: https://www.who.int/publications/i/item/9789240063129 Gewitz AD, Solans BP, Mac Kenzie WR, Heilig C, Whitworth WC, Johnson JL, et al. Longitudinal model-based biomarker analysis of exposure-response relationships in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2021;65(10):10–1128. ClinicalTrials.gov. Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis [Internet]. [cited 2024 Jul 22]. Available from: https://clinicaltrials.gov/study/NCT06058299 Ernest JP, Goh JJN, Strydom N, Wang Q, van Wijk RC, Zhang N, et al. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. Eur Respir J. 2023;62(2):2300165. Jindani A, Doré CJ, Mitchison DA. Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days. Am J Respir Crit Care Med. 2003;167(10):1348–54. Nyang’wa Bern-Thomas, Catherine B, Emil K, Ilaria M, Nargiza P, Zinaida T, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331–43. Andrews J. To be or not to be exclusive: the sutezolid story. Lancet Glob Health. 2016;4(2):e89–90. Sarathy Jansy P, Min X, Adrienne JRMC, Paulina O, Danielle W, et al. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum. mBio. 2023;14(2):e00598–23. Alffenaar JWC, van der Laan T, Simons S, van der Werf TS, van de Kasteele PJ, de Neeling H, et al. Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480. Antimicrob Agents Chemother. 2011;55(3):1287–9. Tables Tables 1 to 3 are available in the Supplementary Files section. Supplementary Files Table13.docx RADTBprotocolpapersupplementv1.1.docx Cite Share Download PDF Status: Under Review Version 1 posted Reviewers agreed at journal 03 Apr, 2025 Reviewers invited by journal 20 Mar, 2025 Editor invited by journal 04 Mar, 2025 Editor assigned by journal 25 Feb, 2025 First submitted to journal 24 Feb, 2025 Editorial decision: Major revision 22 Feb, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5931694","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":431573113,"identity":"163c2abd-ba18-46fc-b03a-b1de78a853f0","order_by":0,"name":"Linda Harrison","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAElEQVRIiWNgGAWjYBACPgkQacDAwA8mGQ5AhHkYGBgbcGhhg2mRbCBNC0jXAaK1SDc/+1xRUCdnfP7wxg8/GO7Im89IfvbhDYON7IYDOLTIHDOeecbgsLHZjbRiyR6GZ4ZzbqQZz5zDkGaMU4tEgjFjg8GBxG03eAykGRgOM87gOWDMzMNwOBG3lvTPQC11iZv7zxj/Bmqxn8Fz/DNQy388WnJAtjAnbmDIMQPZkjiDvQdkywF8WoqBWg4bS9xIK7PsMTicDNRSzDjHINl4Jg4t/BLpmxkb/tTJ8fcf3nzjR8Vh2xnM7JsZ3lTYyfbh0IIGDDAYo2AUjIJRMArIAQAlBlkkTBdb3QAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0000-0002-3170-0865","institution":"Harvard University T H Chan School of Public Health","correspondingAuthor":true,"prefix":"","firstName":"Linda","middleName":"","lastName":"Harrison","suffix":""},{"id":431573114,"identity":"6152b37d-2b3c-4905-91e7-91b5a61abfa2","order_by":1,"name":"Gustavo E Velásquez","email":"","orcid":"","institution":"UCSF: University of California San Francisco","correspondingAuthor":false,"prefix":"","firstName":"Gustavo","middleName":"E","lastName":"Velásquez","suffix":""},{"id":431573115,"identity":"4e775aa7-3935-445a-8078-74c97f989670","order_by":2,"name":"Russell R Kempker","email":"","orcid":"","institution":"Emory University","correspondingAuthor":false,"prefix":"","firstName":"Russell","middleName":"R","lastName":"Kempker","suffix":""},{"id":431573116,"identity":"1b947f7b-6c44-4e4f-8f2d-12a4ff443ead","order_by":3,"name":"Marjorie Z Imperial","email":"","orcid":"","institution":"UCSF: University of California San Francisco","correspondingAuthor":false,"prefix":"","firstName":"Marjorie","middleName":"Z","lastName":"Imperial","suffix":""},{"id":431573117,"identity":"e98dd609-1533-44bb-a878-388c5744fda4","order_by":4,"name":"Eric Nuermberger","email":"","orcid":"","institution":"Johns Hopkins University","correspondingAuthor":false,"prefix":"","firstName":"Eric","middleName":"","lastName":"Nuermberger","suffix":""},{"id":431573118,"identity":"3c556677-f1a2-495c-9714-c635ac3d9473","order_by":5,"name":"Susan E Dorman","email":"","orcid":"","institution":"Medical University of South Carolina","correspondingAuthor":false,"prefix":"","firstName":"Susan","middleName":"E","lastName":"Dorman","suffix":""},{"id":431573119,"identity":"5bd1ba51-53c9-4b89-89c0-c5e2f28b344f","order_by":6,"name":"Elisa Ignatius","email":"","orcid":"","institution":"Johns Hopkins University","correspondingAuthor":false,"prefix":"","firstName":"Elisa","middleName":"","lastName":"Ignatius","suffix":""},{"id":431573120,"identity":"474ee9af-8f46-413c-9415-43a9ae6ee547","order_by":7,"name":"Janeway Granche","email":"","orcid":"","institution":"Harvard University T H Chan School of Public Health","correspondingAuthor":false,"prefix":"","firstName":"Janeway","middleName":"","lastName":"Granche","suffix":""},{"id":431573121,"identity":"81d90ffd-c7fe-4b76-bb15-0479b9ed1b80","order_by":8,"name":"Patrick PJ Phillips","email":"","orcid":"","institution":"UCSF: University of California San Francisco","correspondingAuthor":false,"prefix":"","firstName":"Patrick","middleName":"PJ","lastName":"Phillips","suffix":""},{"id":431573122,"identity":"91403b75-f0d6-4df4-adc0-5e22af94a657","order_by":9,"name":"Jennifer Furin","email":"","orcid":"","institution":"Case Western Reserve University","correspondingAuthor":false,"prefix":"","firstName":"Jennifer","middleName":"","lastName":"Furin","suffix":""},{"id":431573123,"identity":"28b94bb6-bcb1-4671-85d0-983da7aac09e","order_by":10,"name":"Eunsol Yang","email":"","orcid":"","institution":"UCSF: University of California San Francisco","correspondingAuthor":false,"prefix":"","firstName":"Eunsol","middleName":"","lastName":"Yang","suffix":""},{"id":431573124,"identity":"f89d9462-a5ba-4572-8d9a-9f64aee2d47d","order_by":11,"name":"Colleen Foley","email":"","orcid":"","institution":"Frontier Science Foundation","correspondingAuthor":false,"prefix":"","firstName":"Colleen","middleName":"","lastName":"Foley","suffix":""},{"id":431573125,"identity":"8bbfcc4f-b537-4c4b-974a-7db3e81ad590","order_by":12,"name":"Shawn Chiambah","email":"","orcid":"","institution":"National Institute of Allergy and Infectious Diseases","correspondingAuthor":false,"prefix":"","firstName":"Shawn","middleName":"","lastName":"Chiambah","suffix":""},{"id":431573126,"identity":"6e6ab940-95e2-4e5a-9511-3cb3ba409211","order_by":13,"name":"Rochelle Rogers","email":"","orcid":"","institution":"National Institute of Allergy and Infectious Diseases","correspondingAuthor":false,"prefix":"","firstName":"Rochelle","middleName":"","lastName":"Rogers","suffix":""},{"id":431573127,"identity":"f41808a7-9ebb-429e-a7cd-6d0bf619463e","order_by":14,"name":"Austin Van Grack","email":"","orcid":"","institution":"Social \u0026 Scientific Systems Inc","correspondingAuthor":false,"prefix":"","firstName":"Austin","middleName":"Van","lastName":"Grack","suffix":""},{"id":431573128,"identity":"377ad349-23d5-41b9-a440-0a1d7e1466ec","order_by":15,"name":"Jhoanna Roa","email":"","orcid":"","institution":"Social \u0026 Scientific Systems Inc","correspondingAuthor":false,"prefix":"","firstName":"Jhoanna","middleName":"","lastName":"Roa","suffix":""},{"id":431573129,"identity":"97548439-756f-44bc-ab51-706aa1d5baec","order_by":16,"name":"Justin Shenje","email":"","orcid":"","institution":"University of Cape Town","correspondingAuthor":false,"prefix":"","firstName":"Justin","middleName":"","lastName":"Shenje","suffix":""},{"id":431573130,"identity":"d10f829b-48e3-4bfe-b87b-bfbf38dad558","order_by":17,"name":"Sandy Nerette","email":"","orcid":"","institution":"GHESKIO","correspondingAuthor":false,"prefix":"","firstName":"Sandy","middleName":"","lastName":"Nerette","suffix":""},{"id":431573131,"identity":"dc178b2f-e0dd-468e-903d-113c986a8865","order_by":18,"name":"Cecilia Kanyama","email":"","orcid":"","institution":"UNC Project-Malawi","correspondingAuthor":false,"prefix":"","firstName":"Cecilia","middleName":"","lastName":"Kanyama","suffix":""},{"id":431573132,"identity":"1791c619-9531-4327-a559-82e7635eaeaa","order_by":19,"name":"Rachel Bakyayita Kyeyune","email":"","orcid":"","institution":"Seattle Children's Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Rachel","middleName":"Bakyayita","lastName":"Kyeyune","suffix":""},{"id":431573133,"identity":"a7aba317-b89f-4fc2-a7de-670d9dcb3f75","order_by":20,"name":"Alberto Mendoza-Ticona","email":"","orcid":"","institution":"SES: Socios En Salud Sucursal Peru","correspondingAuthor":false,"prefix":"","firstName":"Alberto","middleName":"","lastName":"Mendoza-Ticona","suffix":""},{"id":431573134,"identity":"de6fbbc5-d73e-4d56-998f-26092e951805","order_by":21,"name":"William Murtaugh","email":"","orcid":"","institution":"UCLA: University of California Los Angeles","correspondingAuthor":false,"prefix":"","firstName":"William","middleName":"","lastName":"Murtaugh","suffix":""},{"id":431573135,"identity":"0d64c821-f7e9-4d7b-b912-ff5f02268ce5","order_by":22,"name":"Salah Foraida","email":"","orcid":"","institution":"Global Alliance for TB Drug Development: TB Alliance","correspondingAuthor":false,"prefix":"","firstName":"Salah","middleName":"","lastName":"Foraida","suffix":""},{"id":431573136,"identity":"38373cfa-039e-4347-b065-f685fffbaea6","order_by":23,"name":"Melanie Goth","email":"","orcid":"","institution":"National Institute of Allergy and Infectious Diseases","correspondingAuthor":false,"prefix":"","firstName":"Melanie","middleName":"","lastName":"Goth","suffix":""},{"id":431573137,"identity":"196b35d5-e50d-4f28-a48a-593331a365ce","order_by":24,"name":"Andrew Vernon","email":"","orcid":"","institution":"National Institute of Allergy and Infectious Diseases","correspondingAuthor":false,"prefix":"","firstName":"Andrew","middleName":"","lastName":"Vernon","suffix":""},{"id":431573138,"identity":"85fcc864-bf9f-424a-9401-e0f5e9b8f7d3","order_by":25,"name":"Kelly E Dooley","email":"","orcid":"","institution":"Vanderbilt University Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Kelly","middleName":"E","lastName":"Dooley","suffix":""},{"id":431573139,"identity":"85ab94c4-0687-4ea3-9576-14899595c065","order_by":26,"name":"Radojka M Savic","email":"","orcid":"","institution":"UCSF: University of California San Francisco","correspondingAuthor":false,"prefix":"","firstName":"Radojka","middleName":"M","lastName":"Savic","suffix":""}],"badges":[],"createdAt":"2025-01-30 16:40:12","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5931694/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5931694/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":79259303,"identity":"05d0c634-37ac-497c-b08b-38f8944475f3","added_by":"auto","created_at":"2025-03-26 09:19:02","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":468842,"visible":true,"origin":"","legend":"\u003cp\u003eRAD-TB (ACTG A5409) Wave 1 Platform Trial Design Schematic\u003c/p\u003e","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-5931694/v1/31351943b900b893ef89fabd.jpeg"},{"id":79259311,"identity":"467cb883-7e0c-4b6a-8349-5e1c32e9d21d","added_by":"auto","created_at":"2025-03-26 09:19:02","extension":"jpeg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":348996,"visible":true,"origin":"","legend":"\u003cp\u003ePower for the Primary Efficacy Analysis\u003c/p\u003e","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-5931694/v1/22f7f90fc7ed9e512f778d39.jpeg"},{"id":80742391,"identity":"ee0008cd-4bb5-455a-bc18-774f52435138","added_by":"auto","created_at":"2025-04-16 14:39:51","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2000606,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5931694/v1/f616649b-8536-41d5-bf44-00b8475a29d6.pdf"},{"id":79259300,"identity":"72164ec3-d0b6-423c-9255-50fad3c6aeec","added_by":"auto","created_at":"2025-03-26 09:19:02","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":30749,"visible":true,"origin":"","legend":"","description":"","filename":"Table13.docx","url":"https://assets-eu.researchsquare.com/files/rs-5931694/v1/dcd5a9c40b5c3f7f85f8fa46.docx"},{"id":79259309,"identity":"e7506495-c353-4ae3-a1ed-fb0175fc3cfd","added_by":"auto","created_at":"2025-03-26 09:19:02","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":95345,"visible":true,"origin":"","legend":"","description":"","filename":"RADTBprotocolpapersupplementv1.1.docx","url":"https://assets-eu.researchsquare.com/files/rs-5931694/v1/c4706aa15739e531a6dbb1d6.docx"}],"financialInterests":"","formattedTitle":"ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","fulltext":[{"header":"Administrative information","content":"\u003cp\u003eNote: The numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/). SPIRIT checklist items {26a}, {26b}, {11d}, {16b}, {16c}, {17a}, {17b}, {18a}, {18b}, {19}, {27}, {33}, {31c}, {5d}, {21a}, {23}, {25}, {31a}, {29}, {24}, {32} and {28} are solely covered in the Supplemental Appendix.\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.1923%;\"\u003e\n \u003cp\u003eTitle {1}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 54.8077%;\"\u003e\n \u003cp\u003eA Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.1923%;\"\u003e\n \u003cp\u003eTrial registration {2a and 2b}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 54.8077%;\"\u003e\n \u003cp\u003eClinicalTrials.gov registration number NCT06192160\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.1923%;\"\u003e\n \u003cp\u003eProtocol version {3}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 54.8077%;\"\u003e\n \u003cp\u003eVersion 2.0 as\u0026nbsp;of March 21, 2024\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.1923%;\"\u003e\n \u003cp\u003eFunding {4}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 54.8077%;\"\u003e\n \u003cp\u003eThe trial is funded by the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) under Award Numbers UM1 AI068634, UM1 AI068636, UM1 AI106701 and UM1 AI179699.\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eSome RAD-TB wave 1 drugs will be donated or provided by the Global Alliance for Tuberculosis Drug Development (\u0026ldquo;TB Alliance\u0026rdquo;).\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.1923%;\"\u003e\n \u003cp\u003eAuthor Details {5a}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 54.8077%;\"\u003e\n \u003cp\u003eSee title page\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.1923%;\"\u003e\n \u003cp\u003eName and contact information for the trial sponsor {5b}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 54.8077%;\"\u003e\n \u003cp\u003eDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID)\u003c/p\u003e\n \u003cp\u003eMelanie Goth, Medical Officer at DAIDS, [email protected]\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.1923%;\"\u003e\n \u003cp\u003eRole of sponsor {5c}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 54.8077%;\"\u003e\n \u003cp\u003eDAIDS participated in the design of the RAD-TB trial and reviewed and approved the protocol prior to initiation. Additionally, TB Alliance reviewed the protocol prior to initiation. The content of publications of the RAD-TB trial are solely the responsibility of the authors and do not necessarily represent the official views of DAIDS, TB Alliance, or the institutions with which the authors are affiliated.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"},{"header":"Introduction","content":"\n\u003ch3\u003eBackground and Rationale {6a}\u003c/h3\u003e\n\u003cp\u003eNew innovations in the treatment of drug-susceptible pulmonary tuberculosis (DS-TB) are urgently needed to shorten treatment duration, enhance outcomes, and provide options for people who cannot tolerate standard therapy. The current standard of care (SOC) treatment for DS-TB was developed over 40 years ago (\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e). It is six-months in length consisting of a two-month intensive phase of isoniazid (INH, H), rifampicin (RIF, R), pyrazinamide (Z), and ethambutol (E), followed by a four-month continuation phase of INH and RIF [HRZE] (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e). The HRZE regimen is generally effective but often needs to be prolonged beyond six months in persons with cavitary lung disease (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e), is associated with low completion rates in some groups (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e), is unforgiving of modest adherence lapses (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e), can cause gastrointestinal, liver, eye, skin, and hypersensitivity adverse events (\u003cspan additionalcitationids=\"CR9\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e), and is complicated by rifamycin-based drug-drug interactions (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e). New drugs and regimens for DS-TB are needed to achieve a success rate of more than 90%, meet key priorities of the Global Plan to End TB (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e), and provide better options for both TB providers and patients that more closely align with target regimen profiles set forth by the World Health Organization (WHO) (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eIn the context of drug-resistant TB, there have been significant advances in regimen development resulting in the registration of bedaquiline (B) and pretomanid (Pa), which when given in combination with linezolid (LZD, L) [BPaL], achieved a 90% treatment success rate in the Nix-TB study (NCT02333799) in six months (\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e) but resulted in adverse events from LZD-related mitochondrial toxicity in a majority of participants, most commonly later in treatment (after the first eight weeks). A follow-on dose- and duration-ranging trial of the LZD component of BPaL, ZeNix (NCT03086486), showed that a lower starting dose of LZD at 600 mg daily resulted in a similar treatment success rate (91%), with fewer participants experiencing treatment-limiting anemia, thrombocytopenia, and neuropathy (\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e). Mouse models have shown that combinations like BPaL that include a diarylquinoline, nitroimidazole, and oxazolidinone, respectively, are highly efficacious with the oxazolidinone being a significant contributor to efficacy (\u003cspan additionalcitationids=\"CR18 CR19\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). BPaL has not been evaluated in clinical trials among persons with DS-TB, and descriptions of its use in persons with DS-TB are limited (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e). Studying BPaL in DS-TB is important scientifically since, beyond providing a new treatment option for those with rifamycin-intolerant DS-TB, differences in populations who acquire DS-TB versus DR-TB and in the biology of rifamycin-susceptible versus rifamycin-resistant \u003cem\u003eMtb\u003c/em\u003e strains may lead to varying treatment responses (\u003cspan additionalcitationids=\"CR24 CR25 CR26\" citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e). Knowledge of the efficacy of BPaL in DS-TB will additionally help to define a pan-TB regimen in the future.\u003c/p\u003e \u003cp\u003eWhile microbiologic and clinical outcomes with BPaL are excellent, mitochondrial toxicities associated with LZD, such as optic and peripheral neuropathy and myelosuppression, are a concern. These toxicities are related to cumulative exposure to the drug and limit our ability to use LZD safely beyond the first 8 weeks of treatment. Other oxazolidinones are in development that are likely to have a lower risk of side effects, as some have inhibitory concentrations against mitochondrial protein synthesis that are significantly higher than LZD. One example, TBI-223, recently completed phase 1 testing (\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e), had a superior toxicity profile compared to LZD in toxicology studies, and had comparable efficacy when replacing LZD in combination with a diarylquinoline and Pa in mouse models (\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e). Secondly, sutezolid (SZD, S) has superior potency compared to LZD \u003cem\u003ein vitro\u003c/em\u003e (\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e) and has demonstrated greater efficacy when administered alone and in combination with BPa in BALB/c mice (\u003cspan additionalcitationids=\"CR18 CR19\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). BALB/c mouse model data indicate that SZD together with BPa outperforms HRZE in bactericidal activity and probability of relapse at a dose of 50 mg/kg daily, which is equivalent to 600\u0026ndash;800 mg daily in humans assuming comparable protein binding. SZD completed phase 2A early bactericidal activity (EBA) testing (\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e), and in the SUDOCU phase 2B trial SZD doses of 600 mg daily, 1200 mg daily, 600 mg twice daily and 800 mg twice daily in combination with bedaquiline, delamanid, and moxifloxacin were investigated. Preliminary safety data suggest there were no dose-limiting safety issues, and pharmacokinetic-pharmacodynamic (PK-PD) analyses suggested there was an exposure-response relationship (\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eWith multiple new chemical entities in the TB drug pipeline (\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e), several trials networks and consortia are planning studies of new multidrug regimens for participants with DS-TB [CRUSH-TB (\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e), PAN-TB (\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e), PanACEA (\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e), UNITE4TB (\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e)], including our own network Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections [ACTG] (\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e). The ACTG will conduct the novel \u0026lsquo;\u003cb\u003eR\u003c/b\u003eandomized, \u003cb\u003eA\u003c/b\u003edaptive, \u003cb\u003eD\u003c/b\u003eose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary TB\u0026rsquo; (RAD-TB) (ACTG A5409, NCT06192160) platform trial (\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e). This paper spotlights wave 1 of the RAD-TB platform, where next-generation oxazolidinones in combination with BPa for the treatment of DS-TB are the primary focus.\u003c/p\u003e\n\u003ch3\u003eTrial Design {8}\u003c/h3\u003e\n\u003cp\u003eRAD-TB is a phase 2, open-label, randomized controlled trial with an adaptive design, evaluating new regimens for the treatment of DS-TB. The trial utilizes a platform protocol that allows for future concurrently randomized treatment regimens to be added in subsequent waves after participants have completed, and outcomes have been evaluated for, the current wave.\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eWave 1\u003c/h2\u003e \u003cp\u003eIn wave 1 of the RAD-TB platform trial, participants with DS-TB will be randomized to one of six arms (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). The first two arms of wave 1 will consist of an 8-week SOC HRZE intensive phase (Arm 1) and an 8-week BPaL intensive phase (Arm 2). In Arms 3A and 3B, LZD will be replaced in the BPa combination with one of two different doses of TBI-223 (1200 mg and 2400 mg daily, respectively). Our current mechanistic PK-PD dose-response model suggests that a TBI-223 daily dose of 1200 mg or 2400 mg will provide responses in combination with BPa that are similar to LZD (\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e). In Arms 4A and 4B, LZD will be replaced in the BPa combination by one of two different doses of SZD (800 mg and 1600 mg daily, respectively). Our translational model indicates that human SZD doses of at least 800 mg daily will be similar to or better than LZD in combination with BPa.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWave 1 will enroll a planned 315 participants concurrently randomized to one of the six arms. Twice as many participants will be randomly allocated to the SOC HRZE arm (Arm 1, n\u0026thinsp;=\u0026thinsp;90) compared to the five experimental treatment arms (Arms 2, 3A-B and 4A-B, n\u0026thinsp;=\u0026thinsp;45 each, or 225 in total). This will ensure a stable within-trial SOC comparison arm. Participants will be treated for a total of 26 weeks; consisting of the 8-week intensive experimental phase followed by an 18-week SOC HR continuation phase. Primary efficacy and safety outcomes will be measured at 6 and 8 weeks after treatment initiation, respectively, and all participants will be followed for 52 weeks post-randomization to assess long-term outcomes. The first 20 participants randomized to each of the experimental treatment arms (Arms 2, 3A-B, 4A-B) who consent will undergo intensive sampling for PK analysis, and all experimental arm participants will undergo sparse PK sampling.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eObjectives {7}\u003c/h3\u003e\n\u003cp\u003e \u003cb\u003eCo-Primary Objectives\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eTo compare mycobacteria growth indicator tube (MGIT) liquid culture time to positivity (TTP) slope over the first 6 weeks of treatment for each experimental treatment arm to the SOC arm.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eTo compare new Grade 3 or higher adverse events (AEs) over the first 8 weeks of treatment for each experimental treatment arm to the SOC arm.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e\n\u003ch3\u003eSecondary Objectives\u003c/h3\u003e\n\u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eTo compare time to stable culture conversion by MGIT liquid culture by week 8 for each experimental treatment arm to the SOC arm.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eTo compare MGIT liquid culture TTP slope over the first 8 weeks of treatment for each experimental treatment arm to the SOC arm.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eTo compare new Grade 3 or higher AEs over 26 weeks of treatment for each experimental treatment arm to the SOC arm.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eTo compare discontinuations of anti-TB drugs for any reason prior to 8 and 26 weeks of treatment for each experimental treatment arm to the SOC arm.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eTo determine the dose- and exposure-response relationships between experimental drug estimated PK parameters with safety and efficacy.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eTo compare a composite of efficacy and safety outcomes using a risk-benefit approach for each experimental treatment arm to the SOC arm.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eTo compare MGIT liquid culture TTP slope over the first 6 weeks of treatment for Arms 3A-3B and Arms 4A-4B compared to Arm 2 (BPaL).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eTo compare durable cure defined by 52 weeks after treatment initiation in each experimental treatment arm to the SOC arm.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e"},{"header":"Methods: Participants, interventions, and outcomes","content":"\u003cdiv id=\"Sec7\"\u003e\n \u003ch2\u003eStudy Setting {9}\u003c/h2\u003e\n \u003cp\u003eThe RAD-TB platform trial will be conducted at international sites of the ACTG trials network located in 13 countries in Africa, Asia, and South America.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec8\"\u003e\n \u003ch2\u003eEligibility Criteria {10}\u003c/h2\u003e\n \u003cp\u003e\u003cstrong\u003eInclusion Criteria\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eOverall, the RAD-TB platform trial will recruit adult participants (\u0026ge;\u0026thinsp;18 years) who have active pulmonary DS-TB and are initiating a course of therapy. Key inclusion criteria are\u003c/p\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003ePulmonary TB identified by a sputum specimen within 7 days of entry that is positive for \u003cem\u003eMycobacterium tuberculosis\u003c/em\u003e (\u003cem\u003eMtb\u003c/em\u003e) and has a semiquantitative result of medium or high by Xpert\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eNo prior history of TB treatment within the last five years\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eDocumentation of susceptibility to INH and RIF\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eFor individuals with HIV, a CD4 count\u0026thinsp;\u0026ge;\u0026thinsp;100cells/mm\u003csup\u003e3\u003c/sup\u003e and currently or planned to be treated with dolutegravir-based antiretroviral therapy\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eNormal laboratory values, a Karnofsky score\u0026thinsp;\u0026ge;\u0026thinsp;60, intention to follow contraception requirements, and ability and willingness to provide informed consent\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n \u003cp\u003e\u003cstrong\u003eExclusion Criteria\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eParticipants with more than 7 days of treatment for the current episode of active TB, extrapulmonary TB, Grade 2 or higher peripheral neuropathy, a QTcF interval\u0026thinsp;\u0026gt;\u0026thinsp;450 ms, a weight\u0026thinsp;\u0026lt;\u0026thinsp;35 kg, or a history of congenital QT prolongation, heart failure, hypothyroidism, bradyarrhythmia, or torsades de pointes will be excluded. Because the safety and efficacy of experimental compounds in this early phase trial have not yet been sufficiently established, individuals who are currently pregnant or breastfeeding will be excluded. See the Supplemental Appendix for a full list of the inclusion and exclusion criteria.\u003c/p\u003e\n\u003c/div\u003e\n\u003ch3\u003eInterventions\u003c/h3\u003e\n\u003cdiv id=\"Sec10\"\u003e\n \u003ch2\u003eExplanation for choice of comparator {6b}\u003c/h2\u003e\n \u003cp\u003eThe study interventions are given during the first 8 weeks of TB treatment and the primary comparator regimen is HRZE SOC (Arm 1). HRZE was chosen as the primary comparator since it is the WHO-recommended regimen for pulmonary DS-TB, thus allowing for a direct comparison of the experimental treatment regimens with the current SOC. This trial also utilizes a second comparator regimen in BPaL (Arm 2). While the primary analysis will compare experimental treatment regimens to HRZE, BPaL will secondarily be compared to the other experimental treatment arms and was chosen since it is a WHO-recommended regimen for DR-TB and its use as an additional internal comparator will enable more informative ranking and prioritization of regimens (See the section on \u0026lsquo;Methods for additional analyses\u0026rsquo; {20b} below for more details). Specifically, comparison of the novel BPa-containing regimens with BPaL will allow for direct comparison of the safety and microbiologic activity of different oxazolidinones.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec11\"\u003e\n \u003ch2\u003eIntervention description {11a}\u003c/h2\u003e\n \u003cp\u003eControl and experimental treatment regimens (weeks 1\u0026ndash;8) in wave 1 of the RAD-TB platform are displayed in Fig. 1 and outlined below:\u003c/p\u003e\n \u003cp\u003eArm 1: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol [HRZE]\u003c/p\u003e\n \u003cp\u003eArm 2: Bedaquiline, Pretomanid, Linezolid [BPaL]\u003c/p\u003e\n \u003cp\u003eArm 3A: Bedaquiline, Pretomanid, TBI-223 (1200mg)\u003c/p\u003e\n \u003cp\u003eArm 3B: Bedaquiline, Pretomanid, TBI-223 (2400mg)\u003c/p\u003e\n \u003cp\u003eArm 4A: Bedaquiline, Pretomanid, Sutezolid (800mg)\u003c/p\u003e\n \u003cp\u003eArm 4B: Bedaquiline, Pretomanid, Sutezolid (1600mg)\u003c/p\u003e\n \u003cp\u003eAll drugs will be given once daily with the doses specified in Fig. 1 and will be provided by the study through week 8. Bedaquiline will be given with a loading dose of 400 mg daily for the first two weeks followed by 200 mg daily for six weeks. After week 8, through week 26, all participants will receive the HR continuation phase through their in-country national TB program (NTP) at doses shown in Fig. 1. Pyridoxine (vitamin B6) will be given with INH based on current local dosing guidelines.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec12\"\u003e\n \u003ch2\u003eCriteria for discontinuing or modifying allocated interventions {11b}\u003c/h2\u003e\n \u003cdiv id=\"Sec13\"\u003e\n \u003ch2\u003eTreatment Interruptions\u003c/h2\u003e\n \u003cp\u003eStudy participants will have up to 70 days (10 weeks) from entry to complete 56 doses (8 weeks) of experimental treatment. Any missed doses should be made up with the same combination of drugs that were missed. For all arms during the first 8 weeks, a partial missed dose, where some but not all study drugs in the assigned regimen were taken, will be considered a full missed dose and will need to be made up at the end of the 8-week experimental treatment period.\u003c/p\u003e\n \u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec14\"\u003e\n \u003ch2\u003eTreatment Discontinuation\u003c/h2\u003e\n \u003cp\u003eParticipants who develop a Grade\u0026thinsp;\u0026ge;\u0026thinsp;3 AE or toxicity thought to be secondary to study drugs or of unknown etiology must be discussed by the site investigator with the trial clinical management committee (CMC), will have all study-provided drugs permanently discontinued, and will be referred to the NTP for completion of their TB treatment according to local SOC. If study-provided drug is permanently discontinued, participants will still be followed through the 52-week visit. If a participant develops visual changes which are considered likely due to the oxazolidinone, then the oxazolidinone (and other study-provided drugs) will be permanently discontinued at any grade of presumed optic neuritis. Participants who become pregnant or begin breastfeeding during the study will be discontinued from study-provided drugs and referred to the NTP for the treatment of their TB according to local SOC, and to a prenatal or postnatal care program for management of their pregnancy or breastfeeding, respectively, according to local SOC. Full criteria for permanent and premature study treatment discontinuation are provided in the Supplemental Appendix.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec15\"\u003e\n \u003ch2\u003eStrategies to improve adherence to interventions {11c}\u003c/h2\u003e\n \u003cp\u003eDirectly observed therapy (DOT) will be performed throughout TB treatment. Each site must follow local TB guidelines about DOT. All drugs must be taken orally, 7 days per week. At least five doses per week must be administered as DOT. Video DOT, use of community health workers, or other strategies used locally for delivering observed therapy are acceptable. Doses taken on weekends and on holidays may be under DOT or self-administered, as permitted by local TB guidelines. Data on adherence including pill intake will be recorded on standardized electronic case report forms (eCRFs). Participants with lower adherence (\u0026lt;\u0026thinsp;95%) will be provided counseling by the site. Additionally, all study participants will have adverse event counseling performed by study staff at entry, and at study weeks 1, 2, 3, 4, 6 and 8.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec16\"\u003e\n \u003ch2\u003eProvisions for post-trial care {30}\u003c/h2\u003e\n \u003cp\u003eParticipants who prematurely discontinue study treatment will be referred to their NTP or local clinic for treatment of their TB according to local SOC, but will be encouraged to continue on study, off study treatment, and receive all evaluations per the schedule of evaluations (SOE) through week 52 (Table 1). The composition of the treatment regimen once a participant is discontinued from the study will be at the discretion of the local clinician, with the trial CMC available as needed to advise.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec17\"\u003e\n \u003ch2\u003eOutcomes {12}\u003c/h2\u003e\n \u003cdiv id=\"Sec18\"\u003e\n \u003ch2\u003ePrimary Efficacy Outcome Measure and Estimand\u003c/h2\u003e\n \u003cp\u003eThe primary efficacy outcome is measured by TTP from longitudinal MGIT liquid culture measurements at weeks 0, 1, 2, 3, 4 and 6 of treatment. The primary efficacy estimand is the difference in mean (experimental arm versus SOC) log\u003csub\u003e10\u003c/sub\u003e TTP slope from longitudinal MGIT liquid culture measurements over the first 6 weeks of treatment.\u003c/p\u003e\n \u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec19\"\u003e\n \u003ch2\u003ePrimary Safety Outcome Measure and Estimand\u003c/h2\u003e\n \u003cp\u003eThe primary safety outcome measure is a new Grade 3 or higher AE through week 8 of treatment. The primary safety estimand is the difference in cumulative proportion (experimental arm versus SOC) of individuals having at least one new Grade 3 or higher AE by week 8 of treatment.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec20\"\u003e\n \u003ch2\u003eSecondary Outcome Measures\u003c/h2\u003e\n \u003cp\u003eThe secondary outcome measures are, as follows:\u003c/p\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003eStable sputum culture conversion by week 8 as measured by culture negative status via MGIT liquid culture at two consecutive measurements.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eTTP slope from longitudinal MGIT liquid culture measurements over the first 8 weeks of treatment.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eNew Grade 3 or higher AE through week 26 of treatment.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003ePermanent discontinuation of study-provided anti-TB drugs due to any reason prior to week 8 of treatment.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003ePermanent discontinuation or temporary discontinuation for \u0026ge;\u0026thinsp;3 days of at least one anti-TB drug due to any reason prior to week 8 of treatment.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003ePermanent discontinuation of at least one anti-TB drug due to any reason prior to week 26 of treatment.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eA composite of stable culture conversion at week 6 of treatment and no new Grade 3 or higher AE through week 8.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eDurable cure by 52 weeks after treatment initiation.\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec21\"\u003e\n \u003ch2\u003eOther Outcome Measures\u003c/h2\u003e\n \u003cp\u003eOther outcome measures are, as follows:\u003c/p\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003eProjected hazard ratio comparing time to stable culture conversion for each experimental treatment arm to SOC.\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eSputum ribosomal RNA synthesis (RS) ratio over the first 8 weeks of treatment and at 26 weeks of treatment (43).\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eMGIT liquid culture results at weeks 1, 2, 3, 4, 6, and 8 of treatment.\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec22\"\u003e\n \u003ch2\u003eParticipant timeline {13}\u003c/h2\u003e\n \u003cp\u003eFollowing informed consent, individuals will be screened for the trial to determine if inclusion and exclusion criteria are met. Eligible participants will be randomized to a treatment assignment at entry. Post-entry, scheduled evaluations will take place weekly until week 4, every two weeks until week 12, then at weeks 16, 20, 26 and 52. Additionally, unscheduled visits will occur at premature treatment or study discontinuation, or when a possible poor treatment response is suspected at or after week 16. Table 1 displays the planned evaluations at each visit [See Supplemental Fig. 1 for the SPIRIT figure]. Sputum for mycobacterial culture in liquid media will be collected at each visit with two sputum samples collected at entry and weeks 4, 6 and 8. At participating sites, open-ended qualitative interviews will be conducted in consenting participants to explore patient preferences for treatment regimens using systematic qualitative methods (44).\u003c/p\u003e\n \u003cdiv id=\"Sec23\"\u003e\n \u003ch2\u003eSample Size {14}\u003c/h2\u003e\n \u003cp\u003eThe sample size in wave 1 will be 45 participants in each experimental treatment arm and 90 participants in the SOC arm (Arm 1). Assuming that 10\u0026ndash;12% of participants will undergo late exclusion, withdraw from the study, or have several missing TTP measurements, we based the power simulation on 80 evaluable participants in the efficacy set in the SOC arm, and 40 in each experimental treatment arm. Using longitudinal liquid culture data from the HRZE arm of a recent large, international Phase 3 trial (TBTC Study 31/ACTG A5349, NCT02410772) (45), we estimated a baseline (intercept) TTP of 0.91 log\u003csub\u003e10\u003c/sub\u003e days and a TTP slope of 0.13 log\u003csub\u003e10\u003c/sub\u003e days per week via a linear mixed-effects model with an additive random intercept (SD\u0026thinsp;=\u0026thinsp;0.101) and slope (SD\u0026thinsp;=\u0026thinsp;0.353) plus a multiplicative random error (SD\u0026thinsp;=\u0026thinsp;0.161). Using these estimates, TTP outcomes over 6 weeks were simulated (1,000 replicates) for a SOC and experimental treatment arm with right-censoring of TTP greater than 42 days. For each simulated dataset, a linear mixed-effects model on the log\u003csub\u003e10\u003c/sub\u003e TTP scale accounting for TTP censoring was fit.\u003c/p\u003e\n \u003cp\u003eBased on this simulation, the trial will provide over 90% power to detect a difference in log\u003csub\u003e10\u003c/sub\u003e TTP slopes of at least 35% with a two-sided 5% significance level for each experimental treatment arm compared to SOC (Fig. 2A). As an example, if the average baseline TTP is 0.91 log\u003csub\u003e10\u003c/sub\u003e days\u0026thinsp;=\u0026thinsp;8.1 days and the TTP increase is 0.13 log\u003csub\u003e10\u003c/sub\u003e days per week in the SOC arm, then by week 4 the TTP will be an average of 27 days for the SOC arm. The trial will have over 90% power to detect a 35% increase in slope on the log\u003csub\u003e10\u003c/sub\u003e TTP scale (Fig. 2B). This translates to being powered to detect an average TTP of 41 days by week 4 for an experimental arm. No adjustment for multiple testing is planned.\u003c/p\u003e\n \u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec24\"\u003e\n \u003ch2\u003eRecruitment {15}\u003c/h2\u003e\n \u003cp\u003ePersons presenting to an international ACTG study site with at least one sputum specimen positive for \u003cem\u003eMtb\u003c/em\u003e by Xpert MTB/RIF Ultra at a medium or high semiquantitative level will be invited to screen for the study. The details of the study will be carefully discussed, and the candidate will be asked to read and sign the informed consent form (ICF). Those who agree will enter screening and will be assessed for eligibility by a local study investigator. If they meet all inclusion and none of the exclusion criteria they will be enrolled. Recruitment to wave 1 is anticipated to take approximately 12 months.\u003c/p\u003e\n \u003cdiv id=\"Sec25\"\u003e\n \u003ch2\u003eAssignment of interventions: allocation\u003c/h2\u003e\n \u003cdiv id=\"Sec26\"\u003e\n \u003ch2\u003eSequence generation {16a}\u003c/h2\u003e\n \u003cp\u003eIn wave 1, participants will be randomly assigned to Arm 1 (SOC) or to one of the five concurrently enrolling experimental treatment arms (Arms 2, 3A-B or 4A-B) in a 2:1:1:1:1:1 ratio. Randomization will be conducted using permuted blocks within each of two strata defined by a medium versus high semiquantitative \u003cem\u003eMtb\u003c/em\u003e result by Xpert MTB/RIF Ultra. Additionally, randomization will be dynamically balanced by site.\u003c/p\u003e\n \u003c/div\u003e\n \u003c/div\u003e\n \u003cdiv id=\"Sec27\"\u003e\n \u003ch2\u003eStatistical Methods\u003c/h2\u003e\n \u003cdiv id=\"Sec28\"\u003e\n \u003ch2\u003eStatistical methods for primary and secondary outcomes {20a}\u003c/h2\u003e\n \u003cp\u003eIn wave 1, all comparisons will primarily be made between concurrently randomized experimental treatment and the SOC arm. Using TTP measurement from longitudinal MGIT liquid culture measurements at weeks 0, 1, 2, 3, 4 and 6 of treatment, we will estimate the difference in the mean (experimental arm versus SOC) log\u003csub\u003e10\u003c/sub\u003e TTP slope over the first 6 weeks of treatment. This primary efficacy outcome will be analyzed in the efficacy set of all randomized participants who take at least one dose of study treatment who do not undergo late exclusion due to either a negative baseline culture or drug resistance by baseline phenotypic testing. Table 2 provides the full estimand and analysis details [per the ICH addendum (46, 47)].\u003c/p\u003e\n \u003cp\u003eFor the primary safety outcome measure, the difference in the cumulative proportion (experimental arm versus SOC) of an individual having at least one new grade 3 or higher AE by week 8 of treatment will be estimated. This outcome will be analyzed in the safety set of all randomized participants who take at least one dose of study treatment (See Table 2 for a full specification of the planned analysis). Details of the planned analysis for the secondary outcome measures are in the Supplemental Appendix.\u003c/p\u003e\n \u003c/div\u003e\n \u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec29\"\u003e\n \u003ch2\u003eInterim Analyses {21b}\u003c/h2\u003e\n \u003cp\u003eWe devised an interim safety stopping guideline to allow early discontinuation of experimental treatment arms if they are unlikely to meet a safety guideline at the end of wave 1 (specified in the next section). The interim safety stopping guideline will be assessed when approximately half the participants in the wave have been randomized and reached 8 weeks of follow-up. At this time the observed difference in the cumulative proportion of new Grade 3 or higher AEs by week 8 for each experimental treatment arm compared to the SOC arm will be estimated. If there is a\u0026thinsp;\u0026gt;\u0026thinsp;30% higher observed probability of a new Grade 3 or higher AE through week 8 compared to SOC, the independent interim review committee will consider stopping that experimental treatment arm. For example, if 9 participants out of 22 (41%) experience a new grade 3 or higher AE on an experimental treatment arm compared to 4 out of a 45 (9%) on the SOC arm, the interim safety stopping guideline will be met. This safety stopping guideline is informed by assuming that approximately 10% of participants in the SOC arm will experience a new Grade 3 or higher AE by week 8 (based on data from S31/A5349 (45)). Given this, when the true difference between an experimental treatment arm and the SOC arm is 40%, there is a high chance (~\u0026thinsp;81%) of meeting the stopping guideline. Whereas, when there is truly no difference between an experimental treatment arm and the SOC arm there is a very low chance (\u0026lt;\u0026thinsp;1%) of meeting the stopping guideline (See Table 3). Additionally, if the interim safety stopping guideline is met there is a high chance the regimen will be unlikely to be considered at the end of wave 1 for further development based on the safety guideline for ranking regimens provided in the next section. Wave 1 will also undergo additional regular safety reviews (see details in the Supplemental Appendix).\u003c/p\u003e\n\u003c/div\u003e\n\u003ch3\u003eMethods for additional analyses {20b}\u003c/h3\u003e\n\u003cp\u003eWhen ranking the TB regimens in wave 1 and deciding which regimens to move forward into subsequent waves of the RAD-TB platform (with four-drug regimens, for example), the totality of internal trial evidence, as well as evidence external to the trial, will be considered. A regimen that has a\u0026thinsp;\u0026gt;\u0026thinsp;15% higher observed probability of a new grade 3 or higher AE through week 8 compared to SOC will be unlikely to be considered. Once a regimen passes this safety guideline, the primary efficacy analysis (TTP slope over the first 6 weeks of TB treatment) will be considered to rank regimens, along with the regimen\u0026rsquo;s risk-benefit profile, the regimen\u0026rsquo;s overall safety and tolerability profile, and PK parameters. Additionally, the mean difference in TTP slopes and associated 95% CIs over the first 6 weeks of treatment for Arms 3A-3B and Arms 4A-4B will be compared to Arm 2.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods in analysis to handle protocol nonadherence and any statistical methods to handle missing data {20c}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe analysis for the primary efficacy and safety outcomes will primarily use a treatment policy approach (46) for intercurrent events via an intention-to-treat analysis strategy (See Table 2). Supplemental analyses will consider a while-on-treatment approach for non-minor treatment changes. Participants with a missing TTP will be considered missing at random given observed TTP measurements and the randomized arm. Participants with an inability to produce sputum with or without induction will be assumed to have a TTP\u0026thinsp;\u0026gt;\u0026thinsp;42 days and to be culture negative.\u003c/p\u003e\n\u003cdiv id=\"Sec31\"\u003e\n \u003ch2\u003eOversight and Monitoring\u003c/h2\u003e\n \u003cdiv id=\"Sec32\"\u003e\n \u003ch2\u003eAdverse event reporting and harms {22}\u003c/h2\u003e\n \u003cp\u003eSeverity of AEs will be graded according to the DAIDS Table\u0026nbsp;(48), except for creatinine, peripheral neuropathy, QT, visual acuity, and color vision, which will use trial-specific severity grading scales. Throughout trial follow-up, all Grade\u0026thinsp;\u0026ge;\u0026thinsp;1 non-laboratory AEs, Grade\u0026thinsp;\u0026ge;\u0026thinsp;2 laboratory AEs, all AEs of special interest, all AEs that lead to a change in study treatment, and any AEs meeting the serious AE (SAE) definition or expedited AE (EAE) reporting requirement (49) will be recorded on the eCRFs within 3 days. AEs of special interest include those related to oxazolidinone use including peripheral neuropathy, optic neuritis, and cytopenias as well as QT prolongation and increased transaminases.\u003c/p\u003e\n \u003c/div\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe ultimate aim of the RAD-TB platform trial is to build an optimized four-drug regimen for the treatment of DS-TB that will have superior efficacy compared to HRZE, the potential to shorten treatment duration, and safety and tolerability that is at least as good as HRZE. Currently, clinicians caring for patients with DS-TB do not have many trial-proven alternatives. Here, we have described the study protocol for wave 1 of the RAD-TB platform trial. Wave 1 will consist of six randomized treatment arms to identify the best oxazolidinone(s) to combine with the BPa backbone. Subsequent waves of the RAD-TB platform trial may include further refinement of successful regimen(s) identified in wave 1 to construct a four-drug regimen for DS-TB; this may include addition of a fourth drug or dose-ranging evaluations of novel agents from different drug classes.\u003c/p\u003e \u003cp\u003eThe study design of the RAD-TB platform trial is innovative in at least four ways. First, RAD-TB includes a strategy to rank the regimens within a wave before advancing regimens to the next wave of the platform. At the end of a wave, a safety guideline will be applied before assessment of efficacy, followed by consideration of other factors such as the regimen\u0026rsquo;s risk-benefit profile and PK parameters. The wave has been designed to include an interim safety review at 50% information so that regimens that are unlikely to meet the end-of-wave safety guideline are stopped early. Second, RAD-TB includes an SOC comparator arm composed of the WHO-recommended treatment for DS-TB, HRZE (Arm 1) (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e), as well as a second comparator of BPaL (Arm 2); a current WHO-recommended treatment for DR-TB (\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e). This allows for a within-trial comparison to a second comparator where only one component of the regimen will be modified relative to the experimental arms. For example, a within-trial comparison of TTP slope will be made between BPaL (Arm 2) and BPa with TBI-223 at 1200 mg daily (Arm 3A). The inclusion of BPaL will also provide a first-ever benchmark of BPaL head-to-head against HRZE in DS-TB. Third, the primary efficacy readout will use longitudinal liquid culture TTP measurements over the first 6 weeks of treatment. The TTP slope will be modeled using analysis techniques appropriate for right-censoring as well as for repeated measures within participants. This allows for an efficient assessment of efficacy in an early phase trial of new TB treatment combinations (\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e). Fourth, RAD-TB will conduct dose-finding within the same trial infrastructure with two arms for both TBI-223 (Arms 3A and 3B) and SZD (Arms 4A and 4B). This enables efficient determination of the optimal dose of these two oxazolidinones and assessment of dose-response.\u003c/p\u003e \u003cp\u003eRAD-TB puts forward a paradigm-changing advancement in TB drug development. Internally, we refer to RAD-TB as a \u0026lsquo;Phase 2A+\u0026rsquo; design. Having completed Phase 1 testing, TBI-223 will bypass dedicated EBA monotherapy trials (\u0026lsquo;Phase 2A\u0026rsquo;) in its FDA registration pathway. This has opened a new accelerated drug development pathway, which TBAJ-876 (\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e) has also followed. The RAD-TB design permits this through its rich sputum sampling in the intensive phase which, coupled with translational modeling predictions (\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e), will provide efficacy and safety data for TBI-223 that will stand in for the data generated in Phase 2A. And, as a dose-ranging study of combination therapy with follow-up through 52 weeks post-randomization, RAD-TB will serve the role of what is traditionally considered a Phase 2B trial for both TBI-223 and SZD. This is a welcome advance for TB drug development, where Phase 2A studies have been instrumental to the evaluation of the efficacy of single drugs \u0026mdash; but are susceptible to false negatives where lack of robust EBA may be misconstrued as lack of contribution to multidrug therapy. A salient example is pyrazinamide, which has modest EBA but high sterilizing activity (\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e). Pyrazinamide was critical in shortening standard therapy for DS-TB from 9 to 6 months (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eWave 1 of the RAD-TB trial will generate critical performance and safety data on two novel, promising oxazolidinones, SZD and TBI-223, among persons with DS-TB. While LZD has become a cornerstone drug for the treatment of multidrug- and extensively drug-resistant TB (\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e) based on efficacy demonstrated in the Nix-TB, ZeNix, and TB-PRACTECAL trials (\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e), concerns remain regarding its high rate of AEs, especially when given for more than two months. LZD is associated with myelosuppression and peripheral neuropathy resulting in dose reduction or treatment interruption in many patients. AEs are related to the off-target binding of LZD to mammalian mitochondrial ribosome leading to the inhibition of mitochondrial protein synthesis. The narrow therapeutic window of LZD along with a scarcity of data among persons with DS-TB necessitates further study into alternative oxazolidinones. SZD is a thiomorpholine structural analogue of LZD that was developed alongside LZD but has taken a protracted path to being rigorously tested for TB treatment (\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e). A promising characteristic of SZD is its enhanced potency against \u003cem\u003eMtb\u003c/em\u003e including being more active in caseum (\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e). The minimum inhibitory concentrations of SZD against \u003cem\u003eMtb\u003c/em\u003e clinical isolates have been found to be three times lower than LZD and murine studies have found greater efficacy of BPa and SZD regimens (\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e) versus first-line drug-susceptible therapy and also versus BPa and LZD regimens (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). Additionally, the main metabolite of SZD, U-101603, which is more abundant than the parent compound, has activity against \u003cem\u003eMtb\u003c/em\u003e and appears more active against non-replicating bacteria. Early clinical studies have found SZD to be safe and have bactericidal activity when given for 14 days (\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e). TBI-223 is a newly developed oral oxazolidinone with high bioavailability and substantially reduced inhibition of mammalian mitochondrial protein synthesis. It was developed to optimize the efficacy and safety of oxazolidinone therapy. TBI-223 has activity against drug-susceptible and resistant \u003cem\u003eMtb\u003c/em\u003e isolates from all global lineages and against replicating and non-replicating \u003cem\u003eMtb\u003c/em\u003e. In a murine model, TBI-223 has demonstrated similar bactericidal and sterilizing ability to LZD (\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e). The main advantage of TBI-223 over LZD is its reduced potential for AEs given its low rate of mitochondrial protein synthesis inhibition. Utilizing available pre-clinical and clinical data for SZD as well as unpublished data for TBI-223, our translational pharmacology and modeling tools indicate that BPa with either SZD or TBI-223 will perform as well or better than LZD (\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e). Findings from RAD-TB will thus provide a critical direct comparison of the safety and efficacy of these two promising oxazolidinones, helping to define their role in treating TB.\u003c/p\u003e \u003cp\u003eIn summary, RAD-TB is a platform trial studying early efficacy and safety of TB combination regimens within the ACTG trials network. Wave 1 of the RAD-TB platform will efficiently assess the best oxazolidinone(s) to use in combination with bedaquiline and pretomanid. Subsequent waves will build a safe and well-tolerated regimen that has the potential to be highly efficacious and reduce treatment length. The regimens efficiently identified by the RAD-TB platform will enable future studies of promising combinations that assess long-term outcomes in a large number of participants.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eTrial Status\u003c/strong\u003e \u003cp\u003eAt present, the trial is pending its first enrollment at Protocol version 2.0 dated March 21, 2024. The study opened to screening on February 3, 2025. Accrual in Wave 1 is anticipated to take approximately 12 months after enrollment of the first participant, so Wave 1 recruitment is expected to be completed around March 1, 2026.\u003c/p\u003e \u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eDS-TB, drug-susceptible tuberculosis; BPaL, bedaquiline, pretomanid, linezolid; HRZE, isoniazid, rifampicin, pyrazinamide, ethambutol; RAD-TB, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel regimens for the Treatment of Pulmonary Tuberculosis\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors contributions {31b}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eLJH, GEV and RK wrote the first draft of the manuscript. \u0026nbsp; All authors reviewed and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding {4}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe ACTG A5409 (RAD-TB) platform trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH) under award numbers UM1 AI068634, UM1 AI068636, UM1 AI106701, and UM1 AI179699. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eFox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u0026ndash;1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231\u0026ndash;79.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIseman MD. Tuberculosis therapy: past, present and future. Eur Respir J. 2002;20(Supplement 36):S87\u0026ndash;94.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMurray JF, Schraufnagel DE, Hopewell PC. Treatment of Tuberculosis. A Historical Perspective. Ann Am Thorac Soc. 2015;12(12):1749\u0026ndash;59.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWHO. WHO consolidated guidelines on tuberculosis. Module 4: Treatment - Drug-susceptible tuberculosis treatment. [Internet]. 2022 [cited 2024 Apr 16]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.who.int/publications/i/item/9789240048126\u003c/span\u003e\u003cspan address=\"https://www.who.int/publications/i/item/9789240048126\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorld Health Organization. Target regimen profiles for tuberculosis treatment, 2023 update. World Health Organization; 2023.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCDC. 2021 State and City TB Report [Internet]. [cited 2024 Apr 16]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.cdc.gov/tb/statistics/indicators/2021/completionTherapy.htm\u003c/span\u003e\u003cspan address=\"https://www.cdc.gov/tb/statistics/indicators/2021/completionTherapy.htm\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eImperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708\u0026ndash;15.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTweed C, Wills G, Crook A, Meredith S, Nunn A, Mendel C et al. P119 Using adverse events in a tuberculosis trial to describe the tolerability of standard therapy. 2016.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147\u0026ndash;95.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCDC. Core Curriculum on Tuberculosis. What the Clinician Should Know [Internet]. [cited 2024 Jul 17]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.cdc.gov/tb/media/Core_Curriculum_TB_eBook.pdf\u003c/span\u003e\u003cspan address=\"https://www.cdc.gov/tb/media/Core_Curriculum_TB_eBook.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRegazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug\u0026ndash;drug interactions with rifamycins. Clin Pharmacokinet. 2014;53:489\u0026ndash;507.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSemvua HH, Kibiki GS, Kisanga ER, Boeree MJ, Burger DM, Aarnoutse R. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. Ther Drug Monit. 2015;37(1):22\u0026ndash;32.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStop TB, Partnership. Global Plan to End TB: A blueprint of priority actions and estimate of financial resources needed to end TB [Internet]. [cited 2024 May 28]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.stoptb.org/global-plan-to-end-tb/global-plan-to-end-tb-2023-2030\u003c/span\u003e\u003cspan address=\"https://www.stoptb.org/global-plan-to-end-tb/global-plan-to-end-tb-2023-2030\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUS Food and Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs [Internet]. [cited 2024 Jul 22]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs\u003c/span\u003e\u003cspan address=\"https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eConradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893\u0026ndash;902.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eConradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):810\u0026ndash;23.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, et al. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother. 2016;60(1):270\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWilliams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, et al. Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 2012;56(6):3114\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWilliams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, et al. Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis. Am J Respir Crit Care Med. 2009;180(4):371\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWilliams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, et al. Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model. Antimicrob Agents Chemother. 2009;53(4):1314\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGoswami ND, Ashkin D, Haley CA. Pretomanid in the treatment of patients with tuberculosis in the United States. N Engl J Med. 2022;387(9):850\u0026ndash;2.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHaley CA, Schechter MC, Ashkin D, Peloquin CA, Peter Cegielski J, Andrino BB, et al. Implementation of bedaquiline, pretomanid, and linezolid in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant tuberculosis disease. Clin Infect Dis. 2023;77(7):1053\u0026ndash;62.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCheng N, Wu S, Luo X, Xu C, Lou Q, Zhu J et al. A comparative study of chest computed tomography findings: 1030 cases of drug-sensitive tuberculosis versus 516 cases of drug-resistant tuberculosis. Infect Drug Resist. 2021;1115\u0026ndash;28.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi D, He W, Chen B, Lv P. Primary multidrug-resistant tuberculosis versus drug-sensitive tuberculosis in non-HIV-infected patients: Comparisons of CT findings. PLoS ONE. 2017;12(6):e0176354.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAllu\u0026eacute;-Guardia A, Garc\u0026iacute;a JI, Torrelles JB. Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front Microbiol. 2021;12:612675.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDawson R, Narunsky K, Carman D, Gupte N, Whitelaw A, Efron A, et al. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2015;19(7):780\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTweed C, Wills G, Crook A, Amukoye E, Balanag V, Ban A, et al. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. Int J Tuberc Lung Dis. 2021;25(4):305\u0026ndash;14.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClinicalTrials.gov. A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults [Internet]. [cited 2024 Jul 17]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://clinicaltrials.gov/study/NCT03758612\u003c/span\u003e\u003cspan address=\"https://clinicaltrials.gov/study/NCT03758612\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStrydom N, Ernest JP, Imperial M, Solans BP, Wang Q, Tasneen R, et al. Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen. Nat Commun. 2024;15(1):7311.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi SY, Converse PJ, Betoudji F, Lee J, Mdluli K, Upton A, et al. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model. Antimicrob Agents Chemother. 2023;67(4):e0003523.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T et al. Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis. Pett SL, editor. PLoS ONE. 2014;9(4):e94462.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, et al. Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis. Antimicrob Agents Chemother. 2011;55(2):567\u0026ndash;74.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, et al. Pharmacokinetics and Whole-Blood Bactericidal Activity against \u003cem\u003eMycobacterium tuberculosis\u003c/em\u003e of Single Doses of PNU‐100480 in Healthy Volunteers. J Infect Dis. 2010;202(5):745\u0026ndash;51.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHeinrich N, Opportunistic Infections (CROI). PanACEA SUDOCU Combination Dose-finding Trial Shows Sutezolid is a Safe Oxazolidinone [Internet]. Conference on Retroviruses and ; 2023 [cited 2024 Apr 16]; Seattle, USA. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.croiconference.org/abstract/panacea-sudocu-combination-dose-finding-trial-shows-sutezolid-is-a-safe-oxazolidinone/\u003c/span\u003e\u003cspan address=\"https://www.croiconference.org/abstract/panacea-sudocu-combination-dose-finding-trial-shows-sutezolid-is-a-safe-oxazolidinone/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIgnatius EH, Dooley KE. New Drugs for the Treatment of Tuberculosis. Clin Chest Med. 2019;40(4):811\u0026ndash;27.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorking Group on New TB Drugs. 2024 Global New TB Drug Pipeline [Internet]. [cited 2024 Apr 16]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.newtbdrugs.org/pipeline/clinical\u003c/span\u003e\u003cspan address=\"https://www.newtbdrugs.org/pipeline/clinical\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClinicalTrials.gov. Short-course Regimens for the Treatment of Pulmonary Tuberculosis (CRUSH-TB) [Internet]. [cited 2024 Apr 16]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://clinicaltrials.gov/study/NCT05766267\u003c/span\u003e\u003cspan address=\"https://clinicaltrials.gov/study/NCT05766267\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClinicalTrials.gov. Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis [Internet]. [cited 2024 Apr 16]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://clinicaltrials.gov/study/NCT05971602\u003c/span\u003e\u003cspan address=\"https://clinicaltrials.gov/study/NCT05971602\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClinicalTrials.gov. PanACEA - STEP2C -01 [Internet]. [cited 2024 Apr 16]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://classic.clinicaltrials.gov/ct2/show/NCT05807399\u003c/span\u003e\u003cspan address=\"https://classic.clinicaltrials.gov/ct2/show/NCT05807399\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBoeree MJ, Lange C, Thwaites G, Paton N, De Vrueh R, Barros D, et al. UNITE4TB: A new consortium for clinical drug and regimen development for TB. Int J Tuberc Lung Dis. 2021;25(11):886\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eACTG. Advancing Clinical Therapeutics Globally (ACTG) for HIV/AIDS and Other Infections [Internet]. [cited 2024 Apr 16]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://actgnetwork.org/\u003c/span\u003e\u003cspan address=\"https://actgnetwork.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClinicalTrials.gov. Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB) [Internet]. [cited 2024 Apr 16]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://clinicaltrials.gov/study/NCT06192160\u003c/span\u003e\u003cspan address=\"https://clinicaltrials.gov/study/NCT06192160\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWalter ND, Born SE, Robertson GT, Reichlen M, Dide-Agossou C, Ektnitphong VA, et al. Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. Nat Commun. 2021;12(1):2899.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCorbin J, Strauss A. Basics of qualitative research: Techniques and procedures for developing grounded theory. Sage; 2014.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021;384(18):1705\u0026ndash;18.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eInternational Conference on Harmonisation (ICH). Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Statistical Principles for Clinical Trials E9 (R1) [Internet]. 2019 [cited 2024 Apr 16]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf\u003c/span\u003e\u003cspan address=\"https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKang M, Kendall MA, Ribaudo H, Tierney C, Zheng L, Smeaton L, et al. Incorporating estimands into clinical trial statistical analysis plans. Clin Trials. 2022;19(3):285\u0026ndash;91.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDivision of AIDS (DAIDS). Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events [Internet]. 2017 [cited 2024 Apr 16]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf\u003c/span\u003e\u003cspan address=\"https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eManual for Expedited Reporting. of Adverse Events to DAIDS [Internet]. [cited 2024 Jul 9]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://rsc.niaid.nih.gov/clinical-research-sites/manual-expedited-reporting-adverse-events-daids\u003c/span\u003e\u003cspan address=\"https://rsc.niaid.nih.gov/clinical-research-sites/manual-expedited-reporting-adverse-events-daids\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment - Drug-resistant tuberculosis treatment [Internet]. 2022 [cited 2024 Jul 23]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.who.int/publications/i/item/9789240063129\u003c/span\u003e\u003cspan address=\"https://www.who.int/publications/i/item/9789240063129\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGewitz AD, Solans BP, Mac Kenzie WR, Heilig C, Whitworth WC, Johnson JL, et al. Longitudinal model-based biomarker analysis of exposure-response relationships in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2021;65(10):10\u0026ndash;1128.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClinicalTrials.gov. Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis [Internet]. [cited 2024 Jul 22]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://clinicaltrials.gov/study/NCT06058299\u003c/span\u003e\u003cspan address=\"https://clinicaltrials.gov/study/NCT06058299\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eErnest JP, Goh JJN, Strydom N, Wang Q, van Wijk RC, Zhang N, et al. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. Eur Respir J. 2023;62(2):2300165.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJindani A, Dor\u0026eacute; CJ, Mitchison DA. Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days. Am J Respir Crit Care Med. 2003;167(10):1348\u0026ndash;54.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNyang\u0026rsquo;wa Bern-Thomas, Catherine B, Emil K, Ilaria M, Nargiza P, Zinaida T, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331\u0026ndash;43.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAndrews J. To be or not to be exclusive: the sutezolid story. Lancet Glob Health. 2016;4(2):e89\u0026ndash;90.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSarathy Jansy P, Min X, Adrienne JRMC, Paulina O, Danielle W, et al. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum. mBio. 2023;14(2):e00598\u0026ndash;23.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlffenaar JWC, van der Laan T, Simons S, van der Werf TS, van de Kasteele PJ, de Neeling H, et al. Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480. Antimicrob Agents Chemother. 2011;55(3):1287\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTables 1 to 3 are available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":true,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"trials","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"trls","sideBox":"Learn more about [Trials](http://trialsjournal.biomedcentral.com/)","snPcode":"13063","submissionUrl":"https://www.editorialmanager.com/trls","title":"Trials","twitterHandle":"MedicalEvidence","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"tuberculosis, drug-susceptible, platform trial, bedaquiline, pretomanid, linezolid, TBI-223, sutezolid, time to positivity, early efficacy, randomized controlled trial","lastPublishedDoi":"10.21203/rs.3.rs-5931694/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5931694/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e \u003cb\u003eBackground\u003c/b\u003e \u003c/p\u003e \u003cp\u003eThe standard of care (SOC) treatment for drug-susceptible pulmonary tuberculosis (DS-TB) consists of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). New treatment regimen options for DS-TB are needed as HRZE is long in duration (6 months), associated with frequent adverse events, unforgiving of adherence lapses, and complicated by rifamycin-based drug-drug interactions. The recent resurgence of TB drug development, particularly in the context of drug-resistant TB, offers promise for additional regimens for persons with DS-TB, provided they are sufficiently effective and well-tolerated. We spotlight wave 1 of the RAD-TB platform trial (ACTG A5409, NCT06192160) that will investigate new chemical entities for the treatment of DS-TB.\u003c/p\u003e \u003cp\u003e \u003cb\u003eMethods\u003c/b\u003e \u003c/p\u003e \u003cp\u003e In wave 1 of the RAD-TB platform, adult participants initiating treatment for DS-TB will be randomized to SOC (HRZE, Arm 1) or one of five experimental arms for the 8-week intensive phase. The experimental treatment arms will consist of a bedaquiline and pretomanid backbone (BPa) in combination with one of three oxazolidinones. Arm 2 will study linezolid (BPaL) at a dose of 600 mg daily, Arms 3A and 3B will study TBI-223 at 1200 mg and 2400 mg daily, respectively, and Arms 4A and 4B will study sutezolid at 800 mg and 1600 mg daily, respectively. The primary efficacy objective is to compare sputum culture time to positivity (TTP) slope over the first 6 weeks of treatment for each experimental treatment arm to SOC. The primary safety objective is to compare new Grade 3 or higher adverse events over the first 8 weeks of treatment for each experimental treatment arm to SOC. After the intensive phase, all participants will receive the standard isoniazid and rifampicin (HR) continuation phase for 18 weeks and will be followed for 52 weeks after TB treatment initiation to assess long-term outcomes.\u003c/p\u003e \u003cp\u003e \u003cb\u003eDiscussion\u003c/b\u003e \u003c/p\u003e \u003cp\u003eWave 1 of the RAD-TB platform aims to identify the optimal oxazolidinone(s), with regard to both efficacy and safety, to combine with the BPa backbone for the treatment of DS-TB. Subsequent waves of this platform trial may add a fourth drug to the regimen, study new diarylquinolines to substitute for bedaquiline, or study novel agents from other TB drug classes.\u003c/p\u003e \u003cp\u003e \u003cb\u003eTrials registration\u003c/b\u003e: ClinicalTrials.gov NCT06192160. Registered on January 5, 2024, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://clinicaltrials.gov/study/NCT06192160\u003c/span\u003e\u003cspan address=\"https://clinicaltrials.gov/study/NCT06192160\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/p\u003e","manuscriptTitle":"ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-03-26 09:18:57","doi":"10.21203/rs.3.rs-5931694/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"reviewerAgreed","content":"","date":"2025-04-03T13:59:06+00:00","index":0,"fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-03-20T12:14:09+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"Trials","date":"2025-03-04T11:27:44+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-02-25T07:01:06+00:00","index":"","fulltext":""},{"type":"submitted","content":"Trials","date":"2025-02-24T13:54:54+00:00","index":"","fulltext":""},{"type":"decision","content":"Major revision","date":"2025-02-22T21:52:33+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"trials","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"trls","sideBox":"Learn more about [Trials](http://trialsjournal.biomedcentral.com/)","snPcode":"13063","submissionUrl":"https://www.editorialmanager.com/trls","title":"Trials","twitterHandle":"MedicalEvidence","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"6917e78b-8008-48f2-9d0b-9937af5bd9de","owner":[],"postedDate":"March 26th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2025-07-10T00:25:07+00:00","versionOfRecord":[],"versionCreatedAt":"2025-03-26 09:18:57","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-5931694","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5931694","identity":"rs-5931694","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}